ClinicalTrials.gg
Active, not recruitingNCT02938520Updated Jul 30, 2026Results posted

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

A Phase 3 interventional study of Cabotegravir (CAB) tablet and Rilpivirine (RPV) tablet in HIV Infections, sponsored by ViiV Healthcare. Active, not recruiting at 108 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
631
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing cabotegravir in HIV Infections — 4 open to participants now, 13 under way, 8 of them phase 3. cabotegravir · HIV Infections.

Enrollment
8th of 36
631 · median 200
Started
2016
with 2 others
Phase 3
12 of 36
2 open now
Primary completion
2018-08
later than 1 of 12 live
Registered
11th of 36
by date
Lead sponsor
24 of 36
ViiV Healthcare

Among the 36 studies testing cabotegravir in HIV Infections, this one is the 8th largest by enrollment, is one of 3 that started in 2016, is one of 12 in phase 3, reaches primary completion later than 1 of the 12 other live ones, and was the 11th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

4 of the 36 studies testing cabotegravir in HIV Infections are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About cabotegravir

cabotegravir: first FDA approval 2021 (VOCABRIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing cabotegravir in HIV Infections, or all of them as a file.
02

Study summary

The First Long-Acting Injectable Regimen (FLAIR) study is being conducted to establish if human immunodeficiency virus type-1 (HIV-1) infected adult participants whose virus is virologically suppressed on an integrase inhibitor single tablet regimen (INI STR) will remain suppressed after switching to a two-drug intramuscular (IM) long-acting (LA) regimen of cabotegravir (CAB) and rilpivirine (RPV). In this study, the INI STR will be limited to abacavir/dolutegravir/lamivudine (ABC/DTG/3TC). FLAIR is a Phase 3, multi-phase, randomized, open label, active-controlled, multicenter, parallel-group, non-inferiority study in HIV-1, anti-retroviral therapy (ART)-naïve adult participants. This study is designed to demonstrate the non-inferior antiviral activity of switching to a two drug CAB LA 400 mg + RPV LA 600 mg regimen every 4 weeks (Q4W: monthly) compared to remaining on ABC/DTG/3TC over 48 weeks (4 weeks oral CAB + RPV, 44 weeks LA therapy). Participants who are HLA-B*5701 positive at Screening may enroll into the study and receive DTG plus a non-abacavir containing dual nucleoside reverse transcriptase inhibitor (NRTI) regimen. Eligible participants will enroll into the Induction Phase of the study and receive ABC/DTG/3TC for 20 weeks (Week [-20] to Day 1). Participants who have an HIV 1 ribose nucleic acid (RNA) \<50 copies per milliliter (c/mL) at Week (-4) will be randomized (1:1) into the Maintenance Phase at Day 1 to either continue ABC/DTG/3TC or to discontinue ABC/DTG/3TC and begin oral therapy with CAB 30 mg + RPV 25 mg once daily for approximately 4 Weeks, followed by monthly CAB LA + RPV LA injections from visit Week 4b until study completion or withdrawal. Participants who successfully complete Week 100 (without meeting study defined withdrawal criteria and who remain virologically suppressed through Week 96: HIV-1 RNA \<50 c/mL) will be given the option to switch to the LA arm in the Extension Phase (using an optional oral lead-in with CAB + RPV) or be withdrawn from the study. Participants will continue to receive injections every 4 weeks during the Extension Phase until CAB LA and RPV LA are either locally approved and commercially available, the participant no longer derives clinical benefit, the participant meets a protocol-defined reason for discontinuation, or until development of either CAB LA or RPV LA is terminated.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • Antiretroviral agent
  • Maintenance
  • rilpivirine
  • dolutegravir
  • TMC278
  • Triumeq
  • non-nucleoside reverse transcriptase inhibitor
  • once monthly, every 4 weeks, once daily
  • GSK1265744
  • CAB
  • Tivicay
  • Long-Acting Intramuscular rilpivirine
  • lamivudine
  • integrase inhibitor
  • Long-Acting Intramuscular Cabotegravir
  • ART naïve
  • cabotegravir
  • abacavir
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: - -1 infected, ART-naive men or women aged 18 years or greater at the time of signing the . - HIV-1 infection as documented by Screening plasma HIV-1 RNA >=1000 c/mL; - Antiretroviral-naive (\<=10 days of prior therapy with any antiretroviral agent following a diagnosis of HIV-1 infection). Any previous exposure to an HIV integrase inhibitor or non-nucleoside reverse transcriptase inhibitor will be exclusionary. - Female Participants: A female participant is eligible to participate if she is not pregnant at Screening and first day of Induction Phase (as confirmed by a negative serum human chorionic gonadotrophin [hCG] test), not lactating, and at least one of the following conditions applies: Non- defined as: Pre-menopausal females with one of the following: Documented tubal ligation; Documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion; Hysterectomy; Documented Bilateral Oophorectomy; defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) and estradiol levels consistent with menopause. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment. Reproductive potential and agrees to follow one of the options listed in the Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential (FRP) from 30 days prior to the first dose of study medication, throughout the study, and for at least 30 days after discontinuation of all oral study medications and for at least 52 weeks after discontinuation of CAB LA and RPV LA. The investigator is responsible for ensuring that participants understand how to properly use these methods of contraception. All participants in the study should be counseled on safer sexual practices including the use and benefit/risk of effective barrier methods (e.g., male condom) and on the risk of HIV transmission to an uninfected partner. - Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the consent form and in this protocol. - In France, a participant will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.

Exclusion Criteria: - Women who are pregnant, breastfeeding, or plan to become pregnant or breastfeed during the study. - Any evidence at Screening of an active Centers for Disease and Prevention Control (CDC) Stage 3 disease, except cutaneous Kaposi's sarcoma not requiring systemic therapy or historic or current cluster of differentiation4+ (CD4+) cell count \<200 cells/ cubic millimeter (mm\^3) are not exclusionary. - Participants with known moderate to severe hepatic impairment. - Any pre-existing physical or mental condition (including substance abuse disorder) which, in the opinion of the Investigator, may interfere with the participant's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the participant. - Participants determined by the Investigator to have a high risk of seizures, including participants with an unstable or poorly controlled seizure disorder. A participant with a prior history of seizure may be considered for enrolment if the Investigator believes the risk of seizure recurrence is low. All cases of prior seizure history should be discussed with the Medical Monitor prior to enrolment. - Participant who, in the investigator's judgment, poses a significant suicide risk. Participant's recent history of suicidal behavior and/or suicidal ideation should be considered when evaluating for suicide risk. - The participant has a tattoo or other dermatological condition overlying the gluteus region which may interfere with interpretation of injection site reactions. - Evidence of virus (HBV) infection based on the results of testing at Screening for Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (anti HBc), Hepatitis B surface antibody (anti-HBs) and HBV dioxyribose nucleic acid (DNA) as follows: Participants positive for HBsAg are excluded; Participants negative for anti-HBs but positive for anti-HBc (negative HBsAg status) and positive for HBV DNA are excluded. Note: Participants positive for anti-HBc (negative HBsAg status) and positive for anti-HBs (past and/or current evidence) are immune to HBV and are not excluded. - Asymptomatic individuals with chronic virus (HCV) infection will not be excluded, however Investigators must carefully assess if therapy specific for HCV infection is required; participants who are anticipated to require HCV treatment prior to Week 48 of the Maintenance Phase must be excluded. HCV treatment on study may be permitted post Week 48, following consultation with the Medical Monitor. Participants with HCV co-infection will be allowed entry into Phase 3 studies if: Liver enzymes meet entry criteria; HCV Disease has undergone appropriate work-up, HCV is not advanced, and will not require treatment prior to the Week 48 visit. Additional information (where available) on participants with HCV co-infection at screening should include results from any liver , fibroscan, ultrasound, or other fibrosis evaluation, history of cirrhosis or other decompensated liver disease, prior treatment, and timing/plan for HCV treatment. In the event that recent biopsy or imaging data is not available or is inconclusive, the Fib-4 score will be used to verify eligibility. A Fib-4 score > 3.25 is exclusionary; Fib-4 scores 1.45 - 3.25 requires Medical Monitor consultation. Fibrosis 4 Score Formula: (Age x )/( x [square root of ALT]). - Unstable liver disease (as defined by any of the following: presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice), known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones or otherwise stable chronic liver disease per investigator assessment). - History of liver cirrhosis with or without hepatitis viral co-infection. - Ongoing or pancreatitis. - All participants will be screened for syphilis (rapid plasma reagin [RPR]). Participants with untreated syphilis infection, defined as a positive RPR without clear documentation of treatment, are excluded. Participants with a positive RPR test who have not been treated may be rescreened at least 30 days after completion of antibiotic treatment for syphilis. - Ongoing other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma, or cervical, anal or penile intraepithelial neoplasia; other localized malignancies require agreement between the investigator and the study Medical Monitor for inclusion of the participant prior to enrollment. - Any condition which, in the opinion of the Investigator, may interfere with the absorption, distribution, metabolism or excretion of the drug or render the participant unable to receive study medication. - History or presence of allergy or intolerance to the study drugs or their components or drugs of their class. In addition, if heparin is used during pharmacokinetic sampling (PK) sampling, participants with a history of sensitivity to heparin or heparin-induced thrombocytopenia must not be enrolled. - Current or anticipated need for chronic anti-coagulation. - Alanine aminotransferase (ALT) >=3 times upper limit normal (). - Clinically significant cardiovascular disease, as defined by history/evidence of congestive heart failure, symptomatic arrhythmia, angina/ischemia, coronary artery bypass grafting (CABG) surgery or percutaneous transluminal coronary angioplasty (PTCA) or any clinically significant cardiac disease. - Exposure to an experimental drug and/or experimental vaccine within 28 days or 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to the first dose of product (IP). - Treatment with any of the following agents within 28 days of Screening: radiation therapy; cytotoxic chemotherapeutic agents; tuberculosis (TB) therapy, with the exception of treatment of latent TB with isoniazid; Immunomodulators that alter immune responses (such as chronic systemic , interleukins, or interferons). Note: Participants using short-term (e.g. =\<21 day) systemic corticosteroid treatment, topical, inhaled or intranasal corticosteroids are eligible for enrollment. - Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening. - Treatment with any agent, except recognized ART as allowed above, with documented activity against HIV-1 within 28 days of the first dose of IP. - Use of medications which are associated with Torsades de Pointes - Any evidence of primary resistance to non-nuclease reverse transcriptase inhibitors (NNRTIs) (except for K103N which is allowed), or any known resistance to INIs from historical resistance test results. Note: re-tests of Screening genotypes are allowed only at the discretion of the study virologist. - Participants who are HLA-B*5701 positive and are unable to use an nuclease reverse transcriptase inhibitors (NRTI) backbone that does not contain abacavir (participants who are HLA-B*5701 positive may be enrolled if they use a NRTI backbone that does not contain abacavir; HLA-B*5701 positive participants may be excluded from the study if local provision of an alternate NRTI backbone is not possible). - Any verified Grade 4 laboratory abnormality. A single repeat test is allowed during the Screening Phase to verify a result. - Any acute laboratory abnormality at Screening, which, in the opinion of the Investigator, would preclude the participant's participation in the study of an investigational compound. - Participant has estimated \<50 mL/min/1.73m\^2 via the Chronic Kidney Disease Epidemiology Collaboration () equation. - Participants who are currently participating in or anticipate to be selected for any other interventional study.

Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
631 participants (actual)

Study arms

  • Experimental
    CAB LA + RPV LA every 4 weeks

    After Induction Phase with ABC/DTG/3TC (or DTG + two NRTIs), eligible participants will receive oral CAB 30 mg + RPV 25 mg once daily for approximately four weeks. At visit Week 4b subjects will receive an initial loading dose of CAB LA (600 mg) and RPV LA (900 mg) at Week 4b. From Week 8 onwards, subjects will receive CAB LA (400 mg) + RPV LA (600 mg) injections every 4 weeks.

    Drug: Cabotegravir (CAB) tablet · Drug: Rilpivirine (RPV) tablet · Drug: Cabotegravir - Injectable Suspension (CAB LA) · Drug: Rilpivirine - Injectable Suspension (RPV LA)

  • Active comparator
    ABC / DTG / 3TC (600 mg/50mg/300mg) once daily

    After the Induction Phase with ABC/DTG/3TC (or DTG + two NRTIs), eligible participants will continue to receive oral ABC/DTG/3TC (or DTG + two NRTIs) initiated during the Induction Phase for 100 weeks. At the end of the Maintenance Phase, eligible participants receiving ABC/DTG/3TC (or DTG + two NRTIs) have the option to continue in the study by switching to CAB LA + RPV LA in the Extension Phase. These participants will transition to LA dosing at either Week 100 (direct to inject) or Week 104b (if using optional oral lead-in with CAB 30 mg + RPV 25 mg once daily).

    Drug: ABC/DTG/3TC STR - Tablet · Drug: DTG Tablet

Interventions

  • It is a white oval shaped film coated 30 mg tablets for oral administration. CAB Tablet is composed of cabotegravir sodium, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, and white film-coat.

  • It is a 25 mg tablet with off-white, round, biconvex, film-coated and debossed on one side with "TMC" and the other side with "25". Each tablet contains RPV hydrochloride, and the inactive ingredients croscarmellose sodium, lactose monohydrate, magnesium stearate, polysorbate 20, povidone K30 and silicified microcrystalline cellulose.

  • It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection.

  • It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.

  • DrugABC/DTG/3TC STR - Tablet

    It is a purple, biconvex, oval, tablet debossed with "572 Tri" on one side, film-coated tablet contains abacavir sulphate equivalent to 600 mg of abacavir, dolutegravir sodium equivalent to 50 mg dolutegravir, and 300 mg of lamivudine. The inactive ABC/DTG/3TC tablet ingredients include D-mannitol, magnesium stearate, microcrystalline cellulose, povidone, and sodium starch glycolate.

  • It is a yellow, round, biconvex, 50 mg film-coated tablet debossed with "SV 572" on one side and "50" on the other side. Each tablet of DTG also contains the following inactive ingredients: D-mannitol, microcrystalline cellulose, povidone K29/32, sodium starch glycolate, and sodium stearyl fumarate.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Virologic Failure (HIV-1 Ribonucleic Acid [RNA] >=50 Copies Per Millilter [mL]) Using Snapshot Algorithm at Week 48

    Percentage of participants with virologic failure endpoint (HIV-1 RNA\>=50 c/mL) as per Food and Drug Administration (FDA) snapshot algorithm at Week 48 was assessed to demonstrate the noninferior antiviral activity of switching to intramuscular (IM) CAB LA+RPV LA every 4 weeks compared to continuation of ABC/DTG/3TC regimen over 48 weeks in HIV-1 infected ARTexperienced participants. The HIV-1 RNA \>=50 copies/mL per snapshot algorithm was determined by the last on-treatment HIV-1 RNA measurement within the Week 48 analysis visit window (+/- 6 weeks) or at time of discontinuation (if discontinuation occurred prior to Week 48 for reasons other than Adverse Event).

    Time frame: Week 48

Secondary outcomes

  1. Percentage of Participants With HIV-1 RNA <50 Copies/mL Using Snapshot Algorithm at Week 48

    Percentage of participants with plasma HIV-1 RNA \<50 copies/mL at Week 48 using FDA snapshot algorithm was assessed to demonstrate antiviral and immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to continuation of ABC/DTG/3TC. The HIV-1 RNA \<50 copies/mL per snapshot algorithm was determined by last on-treatment HIV-1 RNA measurement within the Week 48 analysis visit window (+/- 6 weeks). Participants with no data in the analysis window were classificated as non-responders.

    Time frame: Week 48

  2. Number of Participants With HIV-1 RNA <200 Copies/mL Using Snapshot Algorithm at Week 48

    Percentage of participants with plasma HIV-1 RNA \<200 copies/mL at Week 48 using the snapshot algorithm was assessed based on the antiviral and immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to continuation of ABC/DTG/3TC

    Time frame: Week 48

  3. Number of Participants With Confirmed Virologic Failure (CVF) During the Maintenance Phase

    The CVF is defined as rebound as indicated by two consecutive plasma HIV-1-RNA levels \>=200 copies/mL after prior suppression to \<200 copies/mL.

    Time frame: Week 48

  4. Absolute Values for Plasma HIV-1 RNA at Week 48

    Plasma for quantitative HIV-1 RNA were collected at indicated time points. Logarithm to base 10 (log10) values for plasma HIV-1 RNA has been presented.

    Time frame: Week 48

  5. Change From Baseline Values for Plasma HIV-1 RNA at Week 48

    Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline was defined as: HIV-1 RNA(log 10) at Week 48 minus HIV-1 RNA(log 10) at Baseline.

    Time frame: Baseline (Day 1) and at Week 48

  6. Absolute Values for CD4+ Lymphocyte Count at Week 48

    Blood samples were collected and CD4+ cell count assessment by flow cyclometry was carried out to evaluate the immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to ABC/DTG/3TC

    Time frame: Week 48

  7. Change From Baseline Values for CD4+ Lymphocyte Count at Week 48

    Blood samples were collected and CD4+ cell count assessment by flow cyclometry was carried out to evaluate the immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to ABC/DTG/3TC. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline was defined as post-dose visit value at Week 48 minus Maintenance Baseline value.

    Time frame: Baseline (Day 1) and Week 48

  8. Number of Participants With Disease Progression

    Data for participants who experienced disease progression to Centers for Disease Control and Prevention (CDC) Stage III or death has been presented. CDC stage is derived according to lowest post baseline CD4+ T-lympohocyte count and/or occurrence of AIDS-defining conditons (per 2014 CDC criteria).

    Time frame: Day 1 up to an average of 59 weeks

  9. Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence temporally associated with the use of a study treatment, whether or not considered related to study treatment. A SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per medical or scientific judgment. Safety Population: all randomized participants who received at least 1 dose of IP during maintenance phase and assessed according to actual treatment received. All Maintenance Phase AEs was presented including AEs with start date occurring on/after date of 1st dose of randomized treatment, up to and including start date of LTFU antiretroviral therapy for participants who discontinued from Q4W arm. Non-SAE counts in \>=5% of participants within any arm is reported

    Time frame: Day 1 up to an average of 59 Weeks

  10. Number of Participants With Severity of Adverse Events

    Severity of adverse events (AEs) were defined as per The Division of acquired immuno deficiency syndrome (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table) Version 2.0, November 2014. Severity grades for AEs were as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (Potentially life-threatening) and Grade 5 were all deaths related to an AE. All Maintenance Phase adverse events have been presented, which includes AEs with start date occuring on or after the date of first dose of randomized study treatment, up to and including the start date of LTFU antiretroviral therapy for participants who discontinued from the Q4W arm.

    Time frame: Up to Week 48

  11. Absolute Values for Hematology Parameters Over Time Including Week 48: Basophils, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets

    Blood samples were collected for the analysis of hematology parameters including basophil, eosinophils, leukocytes, lymphocytes, neutrophils, monocytes, and platelets at indicated time points.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  12. Absolute Values for Hematology Parameters Over Time Including Week 48: Erythrocyte Mean Corpuscular Volume

    Blood samples were collected for the analysis of hematology parameter including erythrocyte mean corpuscular volume at indicated timepoints.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  13. Absolute Values for Hematology Parameters Over Time Including Week 48: Erythrocytes

    Blood samples were collected for the analysis of hematology parameters including erythrocytes at indicated timepoints.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  14. Absolute Values for Hematology Parameters Over Time Including Week 48: Hemoglobin

    Blood samples were collected for the analysis of hematology parameter including hemoglobin at indicated timepoints.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  15. Absolute Values for Hematology Parameters Over Time Including Week 48: Hematocrit

    Blood samples were collected for the analysis of hematology parameters including hematocrit at indicated timepoints.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  16. Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK)

    Blood samples were collected for the analysis of clinical chemistry parameters including ALT, ALP, AST and CK at indicated timepoints.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  17. Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin

    Blood samples were collected for the analysis of clinical chemistry parameter-albumin at indicated timepoints.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  18. Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine

    Blood samples were collected for the analysis of clinical chemistry parameters including bilirubin, creatinine and direct bilirubin at indicated timepoints.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  19. Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48

    Blood samples were collected for the analysis of clinical chemistry parameters which includes total CO2, chloride, glucose, phosphate, potassium, sodium and urea at indicated timepoints.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  20. Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase

    Blood samples were collected for the analysis of clinical chemistry parameter-lipase at indicated timepoints.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  21. Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance.

    Blood samples were collected for the analysis of clinical chemistry parameter-creatinine clearance at indicated timepoints. Glomerular filtration rate (GFR) will be estimated by the central laboratory using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI).

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  22. Absolute Values for Fasting Lipid Panel Overtime Including Week 48

    Blood samples were collected at Baseline and at Week 48 to assess fasting lipids which included total cholesterol, high density lipoprotein (HDL)cholesterol, low density lipoprotein (LDL) cholesterol and triglycerides.

    Time frame: Baseline (Day 1) and at Week 48

  23. Number of Participants With Abnormal Urinalysis Parameter Over Time Including Week 48

    The dipstick test gives results in a semi-quantitative manner and results for urinalysis parameters (ketones, glucose, bilirubin, occult blood, nitrite and blood protein) can be read as positive, trace, 1+, 2+, 3+ and 4+ indicating proportional concentrations in the urine sample. The urine parameters were graded according to DAIDS scale where Grade 1 indicates mild (trace to 1+), Grade 2 indicates moderate (2+) and Grade 3 indicates severe (3+ or higher). Only participants with abnormal findings for urinalysis at any visit has been presented.

    Time frame: Baseline (Day 1) and at Weeks 4, 24 and 48

  24. Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48

    Urine samples were collected for analysis of urine pH. pH is calculated on a scale of 0 to 14, values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH of less than 7 is acidic and a pH of greater than 7 is basic. Normal urine has a slightly acidic pH (5.0-6.0).

    Time frame: Baseline (Day 1) and at Weeks 4, 24 and 48

  25. Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets

    Blood samples were collected for the analysis of hematology parameters including basophil, eosinophils, leukocytes, lymphocytes, neutrophils, monocytes, and platelets at indicated timepoints. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline was defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  26. Change From Baseline for Hematology Parameters: Erythrocyte Mean Corpuscular Volume

    Blood samples were collected for the analysis of hematology parameter including erythrocyte mean corpuscular volume at indicated timepoints. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance phase dose of IP. Change from Baseline was defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  27. Change From Baseline for Hematology Parameters: Erythrocytes

    Blood samples were collected for the analysis of hematology parameters including erythrocytes at indicated timepoints. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance phase dose of IP. Change from Baseline was defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  28. Change From Baseline for Hematology Parameters: Hematocrit

    Blood samples were collected for the analysis of hematology parameters including hematocrit at indicated timepoints. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance phase dose of IP. Change from Baseline was defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  29. Change From Baseline for Hematology Parameters: Hemoglobin

    Blood samples were collected for the analysis of hematology parameter including hemoglobin at indicated timepoints. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  30. Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK

    Blood samples were collected for the analysis of clinical chemistry parameters including ALT, ALP, AST and CK. Baseline values is defined as the latest pre-treatment assessment with a non-missing value. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  31. Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin

    Blood samples were collected for the analysis of clinical chemistry parameter-albumin. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  32. Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine

    Blood samples were collected for the analysis of clinical chemistry parameters including bilirubin, creatinine and direct bilirubin. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  33. Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48

    Blood samples were collected for the analysis of clinical chemistry parameters which includes total CO2, chloride, glucose, phosphate, potassium, sodium and urea. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  34. Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase

    Blood samples were collected for the analysis of clinical chemistry parameter-lipase. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  35. Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance

    Blood samples were collected for the analysis of clinical chemistry parameter-creatinine clearance. GFR will be estimated by the central laboratory using the CKD-EPI. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  36. Change From Baseline Values for Fasting Lipid Panel and Glucose Overtime Including Week 48

    Blood samples were collected at Baseline and at Week 48 to assess glucose and fasting lipids which included total cholesterol, high density lipoprotein (HDL)cholesterol, low density lipoprotein (LDL) cholesterol and triglycerides. Only fasting data is presented for glucose and lipids. Baseline value is defined as the last available fasting recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at Week 48 visit (if collected while fasting) minus the Baseline value.

    Time frame: Baseline (Day 1) and at Week 48

  37. Change From Baseline Values in Urine Albumin/Creatinine Ratio and Urine Protein/Creatinine Ratio Over Time Including Week 48

    Urine biomarker samples were collected for the analysis of urine albumin/creatinine ratio and urine protein/creatinine ratio. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

    Time frame: Baseline (Day 1) and at Weeks 4, 24 and 48

  38. Change From Baseline Values in Urine Creatinine Over Time Including Week 48

    Urine biomarker samples were collected for the analysis of urine creatinine. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

    Time frame: Baseline (Day 1) and at Weeks 4, 24 and 48

  39. Change From Baseline Values in Urine Phosphate Over Time Including Week 48

    Urine biomarker samples were collected for the analysis of urine phosphate. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

    Time frame: Baseline (Day 1) and at Weeks 4, 24 and 48

  40. Change From Baseline Values in Urine Retinol Binding Protein Over Time Including Week 48

    Urine biomarker samples were collected for the analysis of urine retinol binding protein. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

    Time frame: Baseline (Day 1) and at Week 48

  41. Change From Baseline Values in Urine Specific Gravity Over Time Including Week 48

    Urine biomarker samples were collected for the analysis of urine specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. The urine specific gravity was measured as the ratio of urine density compared with water density.

    Time frame: Baseline (Day 1) and at Weeks 4, 24 and 48

  42. Change From Baseline Values in Urine pH Over Time Including Week 48

    Urine samples were collected for analysis of urine pH. pH is calculated on a scale of 0 to 14, values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH of less than 7 is acidic and a pH of greater than 7 is basic. Normal urine has a slightly acidic pH (5.0-6.0). Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

    Time frame: Baseline (Day 1) and at Weeks 4, 24 and 48

  43. Number of Participants Who Discontinued or Withdrawn Due to AEs Over Time Including Week 48

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. All Maintenance Phase adverse events (start date occurring on or after the date of first dose of randomized study treatment) leading to withdrawal have been presented.

    Time frame: Up to Week 48

  44. Percentage Change From Baseline in Fasting Lipids Overtime Including Week 48

    Blood samples were collected at Baseline and at Week 48 to assess fasting lipids which included total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides. Baseline value is defined as the last available recorded fasting value up to and including the date of first Maintenance Phase dose of IP. Percentage change from baseline is calculated as: value at Week 48 (if collected while fasting) minus Baseline value divided by Baseline value multiplied by 100.

    Time frame: Baseline (Day 1) and at Week 48

  45. Number of Participants With Phenotypic Resistance Through Week 48

    Plasma samples were collected and analyzed from participants who met confirmed virologic withdrawal criteria. Phenotypic Resistance data for following drugs :CAB,dolutegravir(DTG),elvitegravir (EVG), raltegravir(RAL),delavirdine(DLV),efavirenz(EFV),etravirine(ETR),nevirapine(NVP),RPV,lamivudine(3TC),abacavir(ABC),emtricitabine(FTC),tenofovir(TDF),zidovudine(ZDV),stavudine(d4T),didanosine(ddI),atazanavir(ATV),darunavir(DRV),fosamprenavir(FPV),indinavir(IDV),lopinavir(LPV),nelfinavir(NFV),ritonavir(RTV), saquinavir(SQV) and tipranavir (TPV) in participants meeting CVF criteria is presented.Phenotypic resistance, partially sensitive, and Sensitive were defined based on fold change(FC) value from Monogram as:resistance (FC\>clinical higher cutoff/biologic cutoff),partially sensitive (FC=clinical higher cutoff and \> clinical lower cutoff),sensitive(FC\<=clinical lower cutoff/biologic cutoff). The CVF population comprised of all participants in ITT-E population who met CVF criteria

    Time frame: Week 48

  46. Number of Participants With Genotypic Resistance Through Week 48

    Plasma samples were collected and analyzed from participants who met confirmed virologic withdrawal criteria. Genotypic Resistance data for the following drugs: DTG, EVG, RAL, DLV, EFV, ETR, NVP, RPV, 3TC, ABC, FTC, TDF, ZDV, d4T, ddI, ATV, DRV, FPV, IDV, LPV, NFV, RTV, SQV and TPV in participants meeting CVF criteria has been presented.

    Time frame: Week 48

  47. Area Under the Curve (AUC) for CAB LA

    AUC values are Bayesian pharmacokinetic (PK) parameter estimates obtained from a population PK meta-analysis of the data collected from studies 201584 and 201585# NCT02951052. Blood samples from the current study 201584 were collected at indicated time points to analyse concentration in plasma for CAB LA. The PK Population includes all participants who received CAB and / or RPV and undergo PK sampling during the study, and provide CAB and /or RPV plasma concentration data.

    Time frame: Pre-dose at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48; 1 Week post-dose at Weeks 5, 41, 2 hours post-dose at Weeks 4 and 48

  48. AUC for RPV LA

    AUC values are Bayesian PK parameter estimates obtained from a population PK meta-analysis of the data collected from studies 201584 and 201585# NCT02951052. Blood samples from the current study 201584 were collected at indicated time points to analyse concentration in plasma for RPV LA

    Time frame: Pre-dose at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48; 1 Week post-dose at Weeks 5, 41, 2 hours post-dose at Weeks 4 and 48

  49. Plasma Trough Concentration (Ctrough) for CAB LA Evaluable

    Blood samples were collected at indicated time points for PK analysis of CAB LA.

    Time frame: Pre-dose at Weeks 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  50. Ctrough for RPV LA Evaluable

    Blood samples were collected at indicated time points for PK analysis of RPV LA.

    Time frame: Pre-dose at Weeks 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  51. Maximum Concentration (Cmax) in Plasma for CAB LA Evaluable at Week 41

    Blood samples will be collected at indicated time points for PK analysis of CAB LA.

    Time frame: Week 41- 1 Week post dose

  52. Cmax in Plasma for RPV LA Evaluable at Week 41

    Blood samples will be collected at indicated time points for PK analysis of RPV LA.

    Time frame: Week 41- 1 Week post dose

  53. Change From Week 5 in Dimension Scores Using Perception of Injection Questionnaire (PIN)-Last Observation Carried Forward (LOCF)

    PIN questionnaire explores bother of pain at injection site and injection site reactions (ISR),anxiety before and after injection, willingness to receive HIV injectable treatment and satisfaction with mode of treatment administration of individuals receiving injection and perceptions associated with receiving injections.This measure contains 21 items: pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside clinical trial. Scores range from 1 to 5; questions are phrased to ensure that 1:most favorable perception of vaccination, and 5:most unfavorable.Dimension scores include bother from ISR, leg movement, sleep and acceptability.Score of a domain is calculated as mean of all items with domain.Higher scores represent worse perception of injection.LOCF was primary method of analysis

    Time frame: Weeks 5 and at Weeks 41 and 48

  54. Percentage of Participants With Extremely or Very Acceptable Pain and Local Reaction: Acceptability Score on PIN Questionnaire

    PIN questionnaire explores bother of pain at injection site and injection site reactions (ISR),anxiety before and after injection, willingness to receive HIV injectable treatment, following visit and satisfaction with mode of treatment administration of individuals receiving injection and perceptions associated with receiving injections.This measure contains 21 items: pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside clinical trial. Scores range from 1 to 5; questions are phrased to ensure that 1:most favorable perception of vaccination, and 5:most unfavorable.Dimension scores include bother from ISR, leg movement, sleep and acceptability.Score of a domain is calculated as mean of all items with domain.Higher scores represent worse perception of injection.LOCF was primary method of analysis.

    Time frame: Weeks 5, 41 and 48

  55. Change From Baseline in Life Satisfaction (LISAT) Using HIV/AIDs-targeted Quality of Life (HATQoL) Questionnaire

    The HATQoL questionnaire was used to assess health related QoL (HRQoL). It comprises of three dimensions: life satisfaction (LISAT), medication worries (MEDWO) and disclosure worries (DISWO). For LISAT domain, each question is scored as 1-5, where 5 corresponds to satisfaction 'all of time' and 1 as 'none of time'. Total score for the LISAT domain (sum of item scores for questions 1a to 1d) is transformed to a 0-100 scale using formula:\[100 divided by (20 minus 4)\]\*(raw total score for LISAT minus 4). Higher the LISAT score, greater satisfaction to life. Transformed dimension score for each domain was summarized and analyzed. LOCF was used as primary method of analysis. Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI. Baseline value is defined as the last available value up to and including the date of first Maintenance phase dose of IP. Change from Baseline value is calculated as value at post-dose visit minus Baseline value.

    Time frame: Baseline (Day 1) and at Weeks 24 and 48

  56. Change From Baseline in HIV Medication, MEDWO Using HATQoL

    The HATQoL questionnaire was used to assess HRQoL. It comprises of three dimensions: LISAT, MEDWO and DISWO. For the MEDWO domain, each question is scored as 1-5, where 5 is associated with medication worry 'none of the time' and 1 as 'all of the time'. The total score for the MEDWO domain (sum of item scores for questions 2a to 3e) is transformed to a 0-100 scale using formula: \[100 divided by (25 minus 5)\]\* (raw total score for MEDWO minus 5). Higher MEDWO scores correspond to lower medication worries. Transformed dimension score for each domain was summarized and analyzed. LOCF was used as primary method of analysis. Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI. Baseline value is defined as the last available value up to and including the date of first Maintenance phase dose of IP. Change from Baseline value is calculated as value at post-dose visit minus Baseline value.

    Time frame: Baseline and at Weeks 24 and 48

  57. Change From Baseline in DISWO Using HATQoL

    The HATQoL questionnaire was used to assess HRQoL. It comprises of three dimensions: LISAT, MEDWO and DISWO. For the DISWO domain, each question is scored as 1-5, where 5 is associated with disclosure worry 'none of the time' and 1 as 'all of the time'. The total score for the DISWO domain (sum of item scores for questions 3a to 3e) is transformed to a 0-100 scale using formula: \[100 divided by (25 minus 5)\]\* (raw total score for DISWO minus 5). Higher DISWO total scores correspond to lower disclosure worries. Transformed dimension score for each domain was summarized and analyzed. LOCF was used as primary method of analysis. Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI. Baseline value is defined as the last available value up to and including the date of first Maintenance phase dose of IP. Change from Baseline value is calculated as value at post-dose visit minus Baseline value.

    Time frame: Baseline and at Weeks 24 and 48

  58. Change From Baseline in Health Status Using 12-item Short Form Survey (SF-12)

    The SF-12 questionnaire consists of 7 questions which measures degree of general health status and mental health distress. Each question is scored 0-5, except for question 2 scored 0-3. HRQoL using SF-12 for physical component summary (PCS) and mental component summary (MCS) were assessed for two treatment groups.Missing component scores was imputed using LOCF.PCS/MCS are calculated using computer software purchased from QualityMetric (http://www.qualitymetric.com).The higher the score, the better will be the health status.Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance phase dose of IP. Change from Baseline value is calculated as value at post-dose visit minus Baseline value.

    Time frame: Baseline and at Weeks 24 and 48

  59. Change From Baseline in Total Treatment Satisfaction Using HIV Treatment Satisfaction Questionnaire (HIVTSQs) at Weeks 4b, 24 and 44

    HIVTSQs (status version) total treatment satisfaction score is computed with 1-11 items. Items 1-11 are summed to produce score with possible range of 0 to 66. Higher the score, greater improvement in satisfaction with treatment; lower score, greater the deterioration in satisfaction with treatment. A score of 0 represents no change. LOCF was primary method of analysis. Baseline value is defined as the last available value up to and including the date of first Maintenance phase dose of IP. Change from Baseline value is calculated as value at post-dose visit minus Baseline value. Adjusted mean and 95% CI of adjusted mean values has been presented.

    Time frame: Baseline and at Weeks 4b, 24 and 44

  60. Change in Treatment Satisfaction Over Time Using HIVTSQc at Week 48

    HIVTSQc (change version) total treatment satisfaction score is computed with 1-11 items. Items 1-11 are summed to produce score with possible range:-33 to 33. Higher scores represent greater improvement in treatment satisfaction compared to satisfaction with treatment received during the induction phase; lower scores representedeterioration in satisfaction with treatment. A score of 0 represents no change. LOCF was primary method of analysis. Baseline value is defined as the last available value up to and including the date of first Maintenance phase dose of IP. Change from Baseline value is calculated as value at post-dose visit minus Baseline value.

    Time frame: Week 48

  61. Change From Baseline in Individual Item Scores of HIVTSQs at Weeks 4b, 24 and 44

    HIVTSQs (status version) is a 12 item questionnaire. The individual item scores are ratedas 6 (very satisfied, convenient, flexible, etc.) to 0 (very dissatisfied, inconvenient, inflexible, etc.). Higher scores represent greater treatment satisfaction as compared to the past few weeks. LOCF was used as primary method of analysis. Baseline value is defined as the last available value up to and including the date of first Maintenance phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

    Time frame: Baseline and at Weeks 4b, 24 and 44

  62. Change From Baseline in Treatment Acceptance at Weeks 8, 24 and 48 Using "General Acceptance" Dimension of the Chronic Treatment Acceptance (ACCEPT) Questionnaire

    ACCEPT questionnaire is generic medication acceptance measure assessing how participants weigh advantages and disadvantages of long-term medication. It consists 25 items, capturing six dimensions. 3 questions focusing on general acceptance of study medication were analyzed. Items scores are rated as 1-5 :1-totally disagree,2-somewhat disagree,3-somewhat agree,4-totally agree and 5-I don't know. The acceptance domain score (ranging from 0 to 100) is calculated using the following formula:100\*(mean of recoded items in dimension minus 1) divided by 2.LOCF was primary method of analysis. Measure type is mean for adjusted mean and dispersion measure: 95% CI. Baseline value is defined as the last available value up to and including the date of first Maintenance phase dose of IP. Change from Baseline value is calculated as value at post-dose visit minus Baseline value.

    Time frame: Baseline and at Weeks 8, 24 and 48

  63. Change From 4b in Tolerability of Injection at Weeks 5, 40 and 41 Using Numeric Rating Scale (NRS) Within CAB LA+RPV LA Arm

    The NRS questionnaire is used to assess the tolerability of injections in CAB LA+RPV LA arm only. The questionnaire consists of one single question and will assess maximum level of pain experienced with the most recent injections ranking from no pain (0) to extreme pain (10). Missing scores was imputed using LOCF.

    Time frame: Weeks 4b, 5, 40 and 41

Other outcomes

  1. Number of Participants With Different Demographic Parameters for Inter-subject Variability

    Blood samples were planned to be collected at indicated time points for PK analysis of CAB LA and RPV LA. Demographic parameters including, but not limited to, age, sex, race, body weight, body mass index, and relevant laboratory parameters were planned to be evaluated as potential predictors of inter subject variability for pharmacokinetic parameters.

    Time frame: Up to Week 48

07

Results

Posted Oct 29, 2019

Participant flow

This non-inferiority study evaluated antiviral activity of switching to intramuscular long acting carbotegravir (CAB) and rilpivirine (RPV) every 4 weeks compared to continuation of abacavir (ABC)/dolutegravir (DTG)/lamivudine (3TC) over 48 weeks in virologically suppressed participants with human immunodeficiency type 1 infection

Participant flow — Overall Study
MilestoneCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Started283283
Completed00
Not completed283283
Withdrew: On-going at the time of analysis258261
Withdrew: Physician decision25
Withdrew: Lost to follow-up22
Withdrew: Withdrawal by subject77
Withdrew: Protocol violation01
Withdrew: Lack of efficacy53
Withdrew: Adverse event94

Outcome measures

PrimaryPercentage of Participants With Virologic Failure (HIV-1 Ribonucleic Acid [RNA] >=50 Copies Per Millilter [mL]) Using Snapshot Algorithm at Week 48

Percentage of participants with virologic failure endpoint (HIV-1 RNA\>=50 c/mL) as per Food and Drug Administration (FDA) snapshot algorithm at Week 48 was assessed to demonstrate the noninferior antiviral activity of switching to intramuscular (IM) CAB LA+RPV LA every 4 weeks compared to continuation of ABC/DTG/3TC regimen over 48 weeks in HIV-1 infected ARTexperienced participants. The HIV-1 RNA \>=50 copies/mL per snapshot algorithm was determined by the last on-treatment HIV-1 RNA measurement within the Week 48 analysis visit window (+/- 6 weeks) or at time of discontinuation (if discontinuation occurred prior to Week 48 for reasons other than Adverse Event).

Time frame:
Week 48
Reported as:
Number · Percentage of Participants
Percentage of Participants With Virologic Failure (HIV-1 Ribonucleic Acid [RNA] >=50 Copies Per Millilter [mL]) Using Snapshot Algorithm at Week 48
Percentage of ParticipantsCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Percentage of Participants With Virologic Failure (HIV-1 Ribonucleic Acid [RNA] >=50 Copies Per Millilter [mL]) Using Snapshot Algorithm at Week 482.12.5
Statistical analysis
  • CAB LA + RPV LA (Q4W) vs ABC/ DTG/ 3TC · Adjusted difference in proportion: -0.4 · 95% CI -2.8 to 2.1
SecondaryPercentage of Participants With HIV-1 RNA <50 Copies/mL Using Snapshot Algorithm at Week 48

Percentage of participants with plasma HIV-1 RNA \<50 copies/mL at Week 48 using FDA snapshot algorithm was assessed to demonstrate antiviral and immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to continuation of ABC/DTG/3TC. The HIV-1 RNA \<50 copies/mL per snapshot algorithm was determined by last on-treatment HIV-1 RNA measurement within the Week 48 analysis visit window (+/- 6 weeks). Participants with no data in the analysis window were classificated as non-responders.

Time frame:
Week 48
Reported as:
Number · Percentage of Participants
Percentage of Participants With HIV-1 RNA <50 Copies/mL Using Snapshot Algorithm at Week 48
Percentage of ParticipantsCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Percentage of Participants With HIV-1 RNA <50 Copies/mL Using Snapshot Algorithm at Week 489493
Statistical analysis
  • CAB LA + RPV LA (Q4W) vs ABC/ DTG/ 3TC · Adjusted difference in proportion: 0.4 · 95% CI -3.7 to 4.5Adjusted difference in proportion was based on Cochran-Mantel Haenszel stratified analysis adjusting for the following baseline stratification factors: sex at birth (Male, Female) and Induction Baseline (Week -20) HIV-1 RNA (\<100,000 \>=100,000 c/mL)
SecondaryNumber of Participants With HIV-1 RNA <200 Copies/mL Using Snapshot Algorithm at Week 48

Percentage of participants with plasma HIV-1 RNA \<200 copies/mL at Week 48 using the snapshot algorithm was assessed based on the antiviral and immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to continuation of ABC/DTG/3TC

Time frame:
Week 48
Reported as:
Number · Percentage of Participants
Number of Participants With HIV-1 RNA <200 Copies/mL Using Snapshot Algorithm at Week 48
Percentage of ParticipantsCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Number of Participants With HIV-1 RNA <200 Copies/mL Using Snapshot Algorithm at Week 4894 (91 to 97)94 (91 to 97)
SecondaryNumber of Participants With Confirmed Virologic Failure (CVF) During the Maintenance Phase

The CVF is defined as rebound as indicated by two consecutive plasma HIV-1-RNA levels \>=200 copies/mL after prior suppression to \<200 copies/mL.

Time frame:
Week 48
Reported as:
Count of participants · Participants
Number of Participants With Confirmed Virologic Failure (CVF) During the Maintenance Phase
ParticipantsCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Number of Participants With Confirmed Virologic Failure (CVF) During the Maintenance Phase43
SecondaryAbsolute Values for Plasma HIV-1 RNA at Week 48

Plasma for quantitative HIV-1 RNA were collected at indicated time points. Logarithm to base 10 (log10) values for plasma HIV-1 RNA has been presented.

Time frame:
Week 48
Reported as:
Mean · log10 copies/mL
Absolute Values for Plasma HIV-1 RNA at Week 48
log10 copies/mLCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Absolute Values for Plasma HIV-1 RNA at Week 481.513 ± 0.09541.518 ± 0.1152
SecondaryChange From Baseline Values for Plasma HIV-1 RNA at Week 48

Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline was defined as: HIV-1 RNA(log 10) at Week 48 minus HIV-1 RNA(log 10) at Baseline.

Time frame:
Baseline (Day 1) and at Week 48
Reported as:
Mean · log10 copies/mL
Change From Baseline Values for Plasma HIV-1 RNA at Week 48
log10 copies/mLCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Change From Baseline Values for Plasma HIV-1 RNA at Week 48-0.006 ± 0.10260.001 ± 0.1435
SecondaryAbsolute Values for CD4+ Lymphocyte Count at Week 48

Blood samples were collected and CD4+ cell count assessment by flow cyclometry was carried out to evaluate the immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to ABC/DTG/3TC

Time frame:
Week 48
Reported as:
Mean · Cells per cubic millimeter
Absolute Values for CD4+ Lymphocyte Count at Week 48
Cells per cubic millimeterCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Absolute Values for CD4+ Lymphocyte Count at Week 48703.2 ± 285.75731.2 ± 272.49
SecondaryChange From Baseline Values for CD4+ Lymphocyte Count at Week 48

Blood samples were collected and CD4+ cell count assessment by flow cyclometry was carried out to evaluate the immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to ABC/DTG/3TC. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline was defined as post-dose visit value at Week 48 minus Maintenance Baseline value.

Time frame:
Baseline (Day 1) and Week 48
Reported as:
Mean · Cells per cubic millimeter
Change From Baseline Values for CD4+ Lymphocyte Count at Week 48
Cells per cubic millimeterCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Change From Baseline Values for CD4+ Lymphocyte Count at Week 4840.2 ± 195.1779.9 ± 194.55
SecondaryNumber of Participants With Disease Progression

Data for participants who experienced disease progression to Centers for Disease Control and Prevention (CDC) Stage III or death has been presented. CDC stage is derived according to lowest post baseline CD4+ T-lympohocyte count and/or occurrence of AIDS-defining conditons (per 2014 CDC criteria).

Time frame:
Day 1 up to an average of 59 weeks
Reported as:
Count of participants · Participants
Number of Participants With Disease Progression
ParticipantsCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Number of Participants With Disease Progression911
SecondaryNumber of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)

An AE is any untoward medical occurrence temporally associated with the use of a study treatment, whether or not considered related to study treatment. A SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per medical or scientific judgment. Safety Population: all randomized participants who received at least 1 dose of IP during maintenance phase and assessed according to actual treatment received. All Maintenance Phase AEs was presented including AEs with start date occurring on/after date of 1st dose of randomized treatment, up to and including start date of LTFU antiretroviral therapy for participants who discontinued from Q4W arm. Non-SAE counts in \>=5% of participants within any arm is reported

Time frame:
Day 1 up to an average of 59 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)
ParticipantsCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Any non-SAE252138
Any SAE1812
SecondaryNumber of Participants With Severity of Adverse Events

Severity of adverse events (AEs) were defined as per The Division of acquired immuno deficiency syndrome (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table) Version 2.0, November 2014. Severity grades for AEs were as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (Potentially life-threatening) and Grade 5 were all deaths related to an AE. All Maintenance Phase adverse events have been presented, which includes AEs with start date occuring on or after the date of first dose of randomized study treatment, up to and including the start date of LTFU antiretroviral therapy for participants who discontinued from the Q4W arm.

Time frame:
Up to Week 48
Reported as:
Count of participants · Participants
Number of Participants With Severity of Adverse Events
ParticipantsCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Grade 193119
Grade 214395
Grade 32310
Grade 481
Grade 500
SecondaryAbsolute Values for Hematology Parameters Over Time Including Week 48: Basophils, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets

Blood samples were collected for the analysis of hematology parameters including basophil, eosinophils, leukocytes, lymphocytes, neutrophils, monocytes, and platelets at indicated time points.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · 10^9 cells per Liter
Absolute Values for Hematology Parameters Over Time Including Week 48: Basophils, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets
10^9 cells per LiterCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Basophils, Baseline (Day 1), n=283, 2830.022 ± 0.01240.022 ± 0.0138
Basophils, Week 4, n=277, 2700.024 ± 0.01360.024 ± 0.0142
Basophils, Week 8, n=210, 2720.023 ± 0.01350.023 ± 0.0122
Basophils, Week 12, n=267, 2720.025 ± 0.01660.023 ± 0.0144
Basophils, Week 16, n=247, 2590.030 ± 0.02120.028 ± 0.0209
Basophils, Week 20, n=247, 2590.035 ± 0.02540.032 ± 0.0256
Basophils, Week 24, n=256, 2600.037 ± 0.02450.036 ± 0.0256
Basophils, Week 28, n=239, 2580.039 ± 0.02490.038 ± 0.0247
Basophils, Week 32, n=246, 2630.044 ± 0.02540.038 ± 0.0246
Basophils, Week 36, n=250, 2590.042 ± 0.02370.040 ± 0.0250
Basophils, Week 40, n=244, 2450.041 ± 0.02480.041 ± 0.0252
Basophils, Week 44, n=249, 2600.040 ± 0.02460.040 ± 0.0257
Basophils, Week 48, n=239, 2580.038 ± 0.02140.038 ± 0.0246
Eosinophils, Baseline (Day 1), n=283, 2830.142 ± 0.12380.141 ± 0.1449
Eosinophils, Week 4, n=277, 2700.164 ± 0.14700.154 ± 0.1535
Eosinophils, Week 8, n=210, 2720.169 ± 0.14010.150 ± 0.1393
Eosinophils, Week 12, n=267, 2720.165 ± 0.13750.157 ± 0.1481
Eosinophils, Week 16, n=247, 2590.177 ± 0.15380.162 ± 0.1434
Eosinophils, Week 20, n=247, 2590.185 ± 0.16170.166 ± 0.1675
Eosinophils, Week 24, n=256, 2600.193 ± 0.15910.172 ± 0.1518
Eosinophils, Week 28, n=239, 2580.206 ± 0.16340.179 ± 0.1659
Eosinophils, Week 32, n=246, 2630.206 ± 0.17790.169 ± 0.1466
Eosinophils, Week 36, n=250, 2590.209 ± 0.20430.172 ± 0.1540
Eosinophils, Week 40, n=244, 2450.203 ± 0.18370.174 ± 0.1495
Eosinophils, Week 44, n=249, 2600.198 ± 0.18670.180 ± 0.1723
Eosinophils, Week 48, n=239, 2580.182 ± 0.15080.172 ± 0.1533
Leukocytes, Baseline (Day 1), n=283, 2835.82 ± 1.7925.68 ± 1.684
Leukocytes, Week 4, n=279, 2726.41 ± 1.9896.11 ± 1.770
Leukocytes, Week 8, n=211, 2756.04 ± 1.8066.00 ± 1.714
Leukocytes, Week 12, n=270, 2755.88 ± 1.5906.08 ± 1.836
Leukocytes, Week 16, n=252, 2656.08 ± 2.0456.11 ± 1.887
Leukocytes, Week 20, n=254, 2656.08 ± 1.7886.15 ± 1.926
Leukocytes, Week 24, n=258, 2646.11 ± 1.8416.16 ± 2.046
Leukocytes, Week 28, n=244, 2636.17 ± 1.9296.17 ± 1.939
Leukocytes, Week 32, n=253, 2666.07 ± 1.9256.12 ± 1.918
Leukocytes, Week 36, n=252, 2596.11 ± 1.9926.23 ± 2.104
Leukocytes, Week 40, n=246, 2535.96 ± 1.7736.12 ± 2.076
Leukocytes, Week 44, n=256, 2626.03 ± 2.0006.19 ± 1.970
Leukocytes, Week 48, n=243, 2605.85 ± 1.8845.99 ± 1.986
Lymphocytes, Baseline (Day 1), n=283, 2832.022 ± 0.68931.957 ± 0.6408
Lymphocytes, Week 4, n=277, 2702.227 ± 0.73212.197 ± 0.7198
Lymphocytes, Week 8, n=210, 2722.102 ± 0.69802.110 ± 0.7015
Lymphocytes, Week 12, n=267, 2722.032 ± 0.60952.117 ± 0.7162
Lymphocytes, Week 16, n=247, 2592.028 ± 0.69312.130 ± 0.7245
Lymphocytes, Week 20, n=247, 2592.028 ± 0.62842.121 ± 0.6995
Lymphocytes, Week 24, n=256, 2602.014 ± 0.64562.111 ± 0.7092
Lymphocytes, Week 28, n=239, 2582.051 ± 0.65922.106 ± 0.6679
Lymphocytes, Week 32, n=246, 2632.037 ± 0.65432.112 ± 0.6950
Lymphocytes, Week 36, n=250, 2592.023 ± 0.68782.098 ± 0.6921
Lymphocytes, Week 40, n=244, 2452.021 ± 0.66462.030 ± 0.6357
Lymphocytes, Week 44, n=249, 2601.997 ± 0.67482.068 ± 0.6754
Lymphocytes, Week 48, n=239, 2581.926 ± 0.61262.003 ± 0.7651
Monocytes, Baseline (Day 1), n=283, 2830.382 ± 0.16660.366 ± 0.1705
Monocytes, Week 4, n=277, 2700.422 ± 0.17780.398 ± 0.1778
Monocytes, Week 8, n=210, 2720.415 ± 0.18240.380 ± 0.1771
Monocytes, Week 12, n=267, 2720.395 ± 0.16620.383 ± 0.1570
Monocytes, Week 16, n=247, 2590.438 ± 0.18590.409 ± 0.1810
Monocytes, Week 20, n=247, 2590.455 ± 0.19270.423 ± 0.1904
Monocytes, Week 24, n=256, 2600.438 ± 0.18590.438 ± 0.1897
Monocytes, Week 28, n=239, 2580.471 ± 0.19160.447 ± 0.2003
Monocytes, Week 32, n=246, 2630.462 ± 0.18980.459 ± 0.2107
Monocytes, Week 36, n=250, 2590.458 ± 0.21160.456 ± 0.2021
Monocytes, Week 40, n=244, 2450.438 ± 0.17400.442 ± 0.2038
Monocytes, Week 44, n=249, 2600.440 ± 0.19070.428 ± 0.1965
Monocytes, Week 48, n=239, 2580.402 ± 0.19110.396 ± 0.1857
Neutrophils, Baseline (Day 1), n=283, 2833.246 ± 1.37153.205 ± 1.2803
Neutrophils, Week 4, n=277, 2703.573 ± 1.56813.342 ± 1.3344
Neutrophils, Week 8, n=210, 2723.334 ± 1.31663.316 ± 1.3588
Neutrophils, Week 12, n=267, 2723.271 ± 1.21513.379 ± 1.4884
Neutrophils, Week 16, n=247, 2593.410 ± 1.72083.432 ± 1.5052
Neutrophils, Week 20, n=247, 2593.406 ± 1.42093.433 ± 1.5620
Neutrophils, Week 24, n=256, 2603.428 ± 1.49383.424 ± 1.6766
Neutrophils, Week 28, n=239, 2583.439 ± 1.53793.423 ± 1.5514
Neutrophils, Week 32, n=246, 2633.367 ± 1.56703.392 ± 1.4892
Neutrophils, Week 36, n=250, 2593.388 ± 1.52153.468 ± 1.6269
Neutrophils, Week 40, n=244, 2453.274 ± 1.36543.477 ± 1.7021
Neutrophils, Week 44, n=249, 2603.398 ± 1.56793.503 ± 1.5486
Neutrophils, Week 48, n=239, 2583.309 ± 1.49233.419 ± 1.5186
Platelets, Baseline (Day 1), n=283, 282226.7 ± 55.39230.6 ± 58.33
Platelets, Week 4, n=278, 269233.1 ± 56.85233.4 ± 56.56
Platelets, Week 8, n=207, 273226.9 ± 53.23232.0 ± 56.31
Platelets, Week 12, n=269, 271226.6 ± 55.07235.5 ± 57.26
Platelets, Week 16, n=251, 263225.5 ± 55.49239.9 ± 70.40
Platelets, Week 20, n=255, 264233.8 ± 60.98243.4 ± 62.06
Platelets, Week 24, n=256, 261233.9 ± 58.12244.2 ± 59.95
Platelets, Week 28, n=245, 258233.7 ± 61.56247.2 ± 63.18
Platelets, Week 32, n=249, 262235.0 ± 62.74245.3 ± 60.25
Platelets, Week 36, n=248, 259237.3 ± 58.56248.1 ± 59.57
Platelets, Week 40, n=244, 254233.9 ± 56.93247.4 ± 63.85
Platelets, Week 44, n=254, 261236.7 ± 58.18249.5 ± 71.56
Platelets, Week 48, n=240, 255232.8 ± 57.07246.0 ± 70.35
SecondaryAbsolute Values for Hematology Parameters Over Time Including Week 48: Erythrocyte Mean Corpuscular Volume

Blood samples were collected for the analysis of hematology parameter including erythrocyte mean corpuscular volume at indicated timepoints.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · Femtoliters
Absolute Values for Hematology Parameters Over Time Including Week 48: Erythrocyte Mean Corpuscular Volume
FemtolitersCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Baseline (Day 1), n=283, 28394.8 ± 4.9494.3 ± 5.69
Week 4, n=279, 27394.1 ± 4.7794.6 ± 5.85
Week 8, n=211, 27592.3 ± 4.8694.6 ± 5.78
Week 12, n=270, 27591.0 ± 4.6494.0 ± 5.81
Week 16, n=254, 26589.9 ± 4.4394.1 ± 5.78
Week 20, n=255, 26789.3 ± 4.4693.9 ± 5.64
Week 24, n=259, 26489.4 ± 4.3393.8 ± 5.69
Week 28, n=246, 26589.3 ± 4.6493.5 ± 5.78
Week 32, n=254, 26789.6 ± 4.6993.6 ± 5.90
Week 36, n=252, 26189.5 ± 4.6594.1 ± 5.65
Week 40, n=246, 25590.3 ± 4.6294.4 ± 6.09
Week 44, n=256, 26290.7 ± 5.0594.6 ± 6.32
Week 48, n=243, 26091.2 ± 5.2195.4 ± 6.60
SecondaryAbsolute Values for Hematology Parameters Over Time Including Week 48: Erythrocytes

Blood samples were collected for the analysis of hematology parameters including erythrocytes at indicated timepoints.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · 10^12 cells per Liter
Absolute Values for Hematology Parameters Over Time Including Week 48: Erythrocytes
10^12 cells per LiterCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Baseline (Day 1), n=283, 2834.59 ± 0.4344.65 ± 0.412
Week 4, n=279, 2734.67 ± 0.4234.62 ± 0.406
Week 8, n=211, 2754.76 ± 0.4354.67 ± 0.410
Week 12, n=270, 2754.82 ± 0.4354.66 ± 0.419
Week 16, n=254, 2654.87 ± 0.4304.66 ± 0.407
Week 20, n=255, 2674.89 ± 0.4184.64 ± 0.410
Week 24, n=259, 2644.87 ± 0.4184.67 ± 0.425
Week 28, n=246, 2654.87 ± 0.4164.69 ± 0.395
Week 32, n=254, 2674.83 ± 0.4354.66 ± 0.418
Week 36, n=252, 2614.82 ± 0.4034.64 ± 0.395
Week 40, n=246, 2554.81 ± 0.4074.63 ± 0.409
Week 44, n=256, 2624.79 ± 0.4254.59 ± 0.403
Week 48, n=243, 2604.74 ± 0.4434.59 ± 0.437
SecondaryAbsolute Values for Hematology Parameters Over Time Including Week 48: Hemoglobin

Blood samples were collected for the analysis of hematology parameter including hemoglobin at indicated timepoints.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · Grams per liter
Absolute Values for Hematology Parameters Over Time Including Week 48: Hemoglobin
Grams per literCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Baseline (Day 1), n=283, 283142.5 ± 13.59143.1 ± 13.51
Week 4, n=279, 273144.3 ± 13.34143.4 ± 13.47
Week 8, n=211, 275143.9 ± 13.84144.7 ± 13.59
Week 12, n=270, 275144.5 ± 13.89144.7 ± 14.66
Week 16, n=254, 265145.3 ± 13.52144.6 ± 13.88
Week 20, n=255, 267145.4 ± 12.69144.8 ± 13.87
Week 24, n=259, 264145.0 ± 13.14145.3 ± 14.07
Week 28, n=246, 265145.3 ± 12.80146.5 ± 14.17
Week 32, n=254, 267145.1 ± 13.37146.2 ± 14.80
Week 36, n=252, 261144.6 ± 12.27146.2 ± 13.85
Week 40, n=246, 255145.9 ± 12.32146.2 ± 13.85
Week 44, n=256, 262145.1 ± 12.79145.0 ± 14.13
Week 48, n=243, 260143.8 ± 13.56145.4 ± 14.56
SecondaryAbsolute Values for Hematology Parameters Over Time Including Week 48: Hematocrit

Blood samples were collected for the analysis of hematology parameters including hematocrit at indicated timepoints.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · Proportion of red blood cells in blood
Absolute Values for Hematology Parameters Over Time Including Week 48: Hematocrit
Proportion of red blood cells in bloodCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Baseline (Day 1), n=283, 2830.4341 ± 0.038890.4370 ± 0.03887
Week 4, n=279, 2730.4387 ± 0.038090.4363 ± 0.03832
Week 8, n=211, 2750.4382 ± 0.040560.4403 ± 0.03978
Week 12, n=270, 2750.4377 ± 0.040200.4373 ± 0.04144
Week 16, n=254, 2650.4366 ± 0.037690.4371 ± 0.03890
Week 20, n=255, 2670.4363 ± 0.035740.4349 ± 0.03839
Week 24, n=259, 2640.4351 ± 0.035800.4366 ± 0.03901
Week 28, n=246, 2650.4342 ± 0.035190.4374 ± 0.03867
Week 32, n=254, 2670.4318 ± 0.036230.4347 ± 0.04025
Week 36, n=252, 2610.4301 ± 0.033920.4349 ± 0.03774
Week 40, n=246, 2550.4328 ± 0.034330.4358 ± 0.03845
Week 44, n=256, 2620.4332 ± 0.035700.4328 ± 0.03847
Week 48, n=243, 2600.4310 ± 0.038750.4361 ± 0.04156
SecondaryAbsolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK)

Blood samples were collected for the analysis of clinical chemistry parameters including ALT, ALP, AST and CK at indicated timepoints.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · International units per liter
Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK)
International units per literCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
ALT, Baseline (Day 1), n=283, 28328.7 ± 125.2719.5 ± 14.76
ALT, Week 4, n=281, 27725.1 ± 64.7417.9 ± 11.10
ALT, Week 8, n=212, 27820.8 ± 17.4318.4 ± 11.34
ALT, Week 12, n=270, 27621.4 ± 16.9419.2 ± 11.29
ALT, Week 16, n=255, 26921.6 ± 17.6120.3 ± 13.34
ALT, Week 20, n=260, 27225.8 ± 72.5119.6 ± 15.78
ALT, Week 24, n=261, 26823.9 ± 31.1419.1 ± 11.91
ALT, Week 28, n=253, 26822.5 ± 19.7819.6 ± 10.73
ALT, Week 32, n=256, 26838.5 ± 293.5519.0 ± 11.56
ALT, Week 36, n=255, 26120.3 ± 13.9221.2 ± 31.68
ALT, Week 40, n=250, 26620.9 ± 17.3219.5 ± 12.35
ALT, Week 44, n=258, 26322.2 ± 27.1419.8 ± 17.43
ALT, Week 48, n=247, 26220.1 ± 21.7819.7 ± 16.58
ALP, Baseline (Day 1), n=283, 28366.5 ± 22.0667.1 ± 22.98
ALP, Week 4, n=281, 27766.2 ± 19.5665.5 ± 17.07
ALP, Week 8, n=212, 27866.8 ± 18.8266.3 ± 17.49
ALP, Week 12, n=270, 27666.8 ± 19.8066.1 ± 17.23
ALP, Week 16, n=255, 26966.7 ± 19.9666.1 ± 17.89
ALP, Week 20, n=260, 27267.6 ± 19.1165.6 ± 16.71
ALP, Week 24, n=261, 26867.1 ± 19.6866.1 ± 17.96
ALP, Week 28, n=253, 26867.4 ± 20.0567.5 ± 18.07
ALP, Week 32, n=256, 26868.0 ± 22.1766.6 ± 17.65
ALP, Week 36, n=255, 26169.5 ± 26.8668.3 ± 20.19
ALP, Week 40, n=250, 26667.4 ± 18.9467.7 ± 18.30
ALP, Week 44, n=258, 26367.7 ± 18.5968.2 ± 18.62
ALP, Week 48, n=247, 26266.4 ± 17.9567.7 ± 18.15
AST, Baseline (Day 1), n=283, 28328.8 ± 90.6622.5 ± 14.80
AST, Week 4, n=281, 27725.1 ± 32.6720.9 ± 8.47
AST, Week 8, n=212, 27823.6 ± 20.8520.5 ± 6.26
AST, Week 12, n=270, 27622.8 ± 10.3821.0 ± 8.14
AST, Week 16, n=255, 26923.0 ± 10.7122.8 ± 14.03
AST, Week 20, n=260, 27225.3 ± 32.6422.7 ± 23.48
AST, Week 24, n=261, 26825.9 ± 25.1621.2 ± 9.73
AST, Week 28, n=253, 26824.8 ± 16.5021.7 ± 10.61
AST, Week 32, n=256, 26837.1 ± 233.2320.7 ± 6.42
AST, Week 36, n=255, 26123.0 ± 12.4422.4 ± 17.37
AST, Week 40, n=250, 26623.1 ± 12.2221.0 ± 6.51
AST, Week 44, n=258, 26324.4 ± 15.6621.9 ± 13.25
AST Week 48, n=247, 26222.3 ± 10.9823.5 ± 42.49
CK, Baseline (Day 1), n=283, 283197.8 ± 291.21199.8 ± 482.84
CK, Week 4, n=280, 277230.2 ± 447.94173.0 ± 220.54
CK, Week 8, n=212, 278258.0 ± 928.82152.9 ± 146.05
CK, Week 12, n=270, 276201.8 ± 348.13182.6 ± 387.61
CK, Week 16, n=255, 269179.7 ± 248.71234.0 ± 576.62
CK, Week 20, n=260, 272215.7 ± 539.34258.9 ± 1109.04
CK, Week 24, n=261, 268248.6 ± 628.44183.1 ± 368.02
CK, Week 28, n=253, 268252.7 ± 673.98194.5 ± 506.24
CK, Week 32, n=256, 268175.8 ± 223.16160.0 ± 176.09
CK, Week 36, n=254, 261219.0 ± 507.30215.2 ± 460.38
CK, Week 40, n=250, 266220.5 ± 507.68149.5 ± 115.14
CK, Week 44, n=258, 263254.0 ± 477.19181.9 ± 428.28
CK, Week 48, n=247, 262185.5 ± 227.54323.6 ± 2637.27
SecondaryAbsolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin

Blood samples were collected for the analysis of clinical chemistry parameter-albumin at indicated timepoints.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · Grams per liter
Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin
Grams per literCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Baseline (Day 1), n=283, 28343.8 ± 3.0444.1 ± 2.80
Week 4, n=280, 27743.7 ± 3.0343.8 ± 2.70
Week 8, n=212, 27843.5 ± 2.8543.9 ± 2.76
Week 12, n=270, 27643.7 ± 3.0644.1 ± 2.87
Week 16, n=255, 26944.1 ± 2.9944.0 ± 2.78
Week 20, n=260, 27244.1 ± 3.1143.9 ± 2.72
Week 24, n=261, 26844.3 ± 3.0844.2 ± 2.60
Week 28, n=253, 26844.4 ± 3.0944.5 ± 2.66
Week 32, n=255, 26844.6 ± 3.1744.4 ± 2.76
Week 36, n=254, 26144.1 ± 3.0544.3 ± 2.63
Week 40, n=250, 26644.8 ± 3.0244.5 ± 2.76
Week 44, n=258, 26344.7 ± 2.9844.4 ± 2.71
Week 48, n=247, 26244.6 ± 2.9844.6 ± 2.86
SecondaryAbsolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine

Blood samples were collected for the analysis of clinical chemistry parameters including bilirubin, creatinine and direct bilirubin at indicated timepoints.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · Micromoles per liter
Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine
Micromoles per literCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Bilirubin, Baseline (Day 1), n=283, 2839.3 ± 5.129.4 ± 4.68
Bilirubin, Week 4, n=281, 27710.7 ± 6.378.9 ± 4.40
Bilirubin, Week 8, n=212, 27810.1 ± 4.628.8 ± 3.85
Bilirubin, Week 12, n=270, 27610.5 ± 5.458.6 ± 3.53
Bilirubin, Week 16, n=255, 26910.6 ± 5.498.7 ± 3.74
Bilirubin, Week 20, n=260, 27210.3 ± 5.298.5 ± 3.40
Bilirubin, Week 24, n=261, 26810.0 ± 5.098.9 ± 3.86
Bilirubin, Week 28, n=253, 26810.4 ± 5.678.6 ± 3.90
Bilirubin, Week 32, n=256, 26810.5 ± 7.868.7 ± 3.95
Bilirubin, Week 36, n=255, 2609.9 ± 6.358.5 ± 3.42
Bilirubin, Week 40, n=250, 26610.2 ± 5.268.5 ± 3.52
Bilirubin, Week 44, n=258, 26310.3 ± 5.158.8 ± 3.78
Bilirubin, Week 48, n=247, 26210.3 ± 5.238.9 ± 3.71
Direct bilirubin, Baseline (Day 1), n=283, 2832.3 ± 1.322.2 ± 1.09
Direct bilirubin, Week 4, n=277, 2772.4 ± 1.472.1 ± 1.08
Direct bilirubin, Week 8, n=212, 2782.4 ± 1.172.1 ± 0.93
Direct bilirubin, Week 12, n=269, 2732.5 ± 1.262.1 ± 0.91
Direct bilirubin, Week 16, n=254, 2682.4 ± 1.462.1 ± 0.95
Direct bilirubin, Week 20, n=260, 2722.4 ± 1.542.1 ± 0.90
Direct bilirubin, Week 24, n=260, 2662.3 ± 1.202.1 ± 0.96
Direct bilirubin, Week 28, n=253, 2682.5 ± 1.292.1 ± 0.94
Direct bilirubin, Week 32, n=256, 2682.5 ± 3.482.1 ± 0.94
Direct bilirubin, Week 36, n=255, 2602.4 ± 2.242.0 ± 0.89
Direct bilirubin, Week 40, n=249, 2662.3 ± 1.292.1 ± 0.98
Direct bilirubin, Week 44, n=258, 2632.4 ± 1.342.1 ± 0.95
Direct bilirubin, Week 48, n=247, 2622.3 ± 1.262.2 ± 1.00
Creatinine, Baseline (Day 1), n=283, 28389.00 ± 16.06185.80 ± 15.660
Creatinine, Week 4, n=280, 27782.99 ± 15.59986.43 ± 14.655
Creatinine, Week 8, n=212, 27879.50 ± 14.10385.50 ± 15.925
Creatinine, Week 12, n=270, 27679.25 ± 14.43384.63 ± 15.155
Creatinine, Week 16, n=255, 26979.58 ± 14.50985.18 ± 14.997
Creatinine, Week 20, n=261, 27278.50 ± 13.96685.02 ± 15.488
Creatinine, Week 24, n=262, 26879.10 ± 15.34085.05 ± 14.690
Creatinine, Week 28, n=253, 26878.79 ± 14.74184.38 ± 15.023
Creatinine, Week 32, n=255, 26878.89 ± 14.55884.50 ± 15.047
Creatinine, Week 36, n=254, 26279.58 ± 14.97384.75 ± 14.352
Creatinine, Week 40, n=250, 26679.50 ± 15.61584.70 ± 14.808
Creatinine, Week 44, n=258, 26380.04 ± 15.40183.90 ± 14.604
Creatinine, Week 48, n=247, 26279.95 ± 15.61390.88 ± 87.655
SecondaryAbsolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48

Blood samples were collected for the analysis of clinical chemistry parameters which includes total CO2, chloride, glucose, phosphate, potassium, sodium and urea at indicated timepoints.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · Millimoles per liter
Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48
Millimoles per literCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
CO2, Baseline (Day 1), n=283, 28322.4 ± 2.2422.4 ± 2.10
CO2, Week 4, n=280, 27623.0 ± 2.2922.6 ± 2.28
CO2, Week 8, n=212, 27822.8 ± 2.0722.3 ± 2.27
CO2, Week 12, n=270, 27622.6 ± 2.5022.2 ± 2.34
CO2, Week 16, n=255, 26922.9 ± 2.4022.3 ± 2.50
CO2, Week 20, n=260, 27222.8 ± 2.3022.4 ± 2.32
CO2, Week 24, n=261, 26823.0 ± 2.7122.8 ± 2.19
CO2, Week 28, n=253, 26823.0 ± 2.3122.8 ± 2.47
CO2, Week 32, n=255, 26823.0 ± 2.3122.7 ± 2.35
CO2, Week 36, n=253, 26123.1 ± 2.3722.5 ± 2.26
CO2, Week 40, n=249, 26522.8 ± 2.3422.6 ± 2.39
CO2, Week 44, n=257, 26322.9 ± 2.3422.4 ± 2.12
CO2, Week 48, n=247, 26222.5 ± 2.1822.3 ± 2.04
Chloride, Baseline (Day 1), n=283, 283104.6 ± 2.32104.3 ± 2.32
Chloride, Week 4, n=280, 277104.6 ± 2.22104.7 ± 2.13
Chloride, Week 8, n=212, 278104.7 ± 1.96104.6 ± 2.32
Chloride, Week 12, n=270, 276104.6 ± 2.16104.7 ± 2.35
Chloride, Week 16, n=255, 269104.4 ± 2.31104.7 ± 2.24
Chloride, Week 20, n=260, 272104.3 ± 2.28104.7 ± 2.06
Chloride, Week 24, n=261, 268104.4 ± 2.33104.5 ± 2.42
Chloride, Week 28, n=253, 268104.5 ± 2.20104.5 ± 2.28
Chloride, Week 32, n=255, 268104.4 ± 2.46104.5 ± 2.33
Chloride, Week 36, n=254, 261104.4 ± 2.42104.7 ± 2.20
Chloride, Week 40, n=250, 266104.8 ± 2.55104.7 ± 2.25
Chloride, Week 44, n=258, 263104.7 ± 2.19105.0 ± 2.22
Chloride, Week 48, n=247, 262104.7 ± 2.21104.7 ± 2.28
Glucose, Baseline (Day 1), n=283, 2835.21 ± 1.6325.17 ± 0.932
Glucose, Week 4, n=236, 2305.27 ± 1.3225.23 ± 0.734
Glucose, Week 8, n=172, 2275.31 ± 1.3475.19 ± 0.644
Glucose, Week 12, n=229, 2165.26 ± 0.9115.27 ± 0.616
Glucose, Week 16, n=204, 2135.36 ± 1.8045.28 ± 0.801
Glucose, Week 20, n=209, 2185.32 ± 0.7355.26 ± 0.634
Glucose, Week 24, n=221, 2145.35 ± 1.2195.21 ± 0.634
Glucose, Week 28, n=207, 2115.35 ± 1.6335.23 ± 0.614
Glucose, Week 32, n=201, 2135.44 ± 1.3555.27 ± 0.600
Glucose, Week 36, n=199, 2045.35 ± 0.7975.31 ± 0.960
Glucose, Week 40, n=203, 2025.44 ± 1.3195.35 ± 0.753
Glucose, Week 44, n=208, 2025.34 ± 0.9915.35 ± 0.709
Glucose, Week 48, n=248, 2515.22 ± 0.8955.22 ± 0.690
Phosphate, Baseline (Day 1), n=283, 2831.103 ± 0.17471.097 ± 0.1765
Phosphate, Week 4, n=279, 2771.137 ± 0.17741.112 ± 0.1850
Phosphate, Week 8, n=212, 2781.096 ± 0.17421.114 ± 0.1858
Phosphate, Week 12, n=270, 2761.097 ± 0.18021.106 ± 0.1876
Phosphate, Week 16, n=255, 2691.104 ± 0.18061.119 ± 0.1823
Phosphate, Week 20, n=260, 2721.078 ± 0.18431.114 ± 0.1812
Phosphate, Week 24, n=261, 2681.106 ± 0.17971.109 ± 0.1791
Phosphate, Week 28, n=253, 2681.094 ± 0.18141.119 ± 0.1893
Phosphate, Week 32, n=255, 2681.105 ± 0.17691.104 ± 0.1945
Phosphate, Week 36, n=254, 2611.102 ± 0.18621.122 ± 0.1872
Phosphate, Week 40, n=250, 2661.093 ± 0.16991.114 ± 0.1837
Phosphate, Week 44, n=258, 2631.096 ± 0.18511.120 ± 0.1903
Phosphate, Week 48, n=247, 2621.096 ± 0.18881.120 ± 0.2341
Potassium, Baseline (Day 1), n=283, 2834.12 ± 0.3014.14 ± 0.288
Potassium, Week 4, n=280, 2774.27 ± 0.3084.20 ± 0.327
Potassium, Week 8, n=212, 2784.22 ± 0.3024.22 ± 0.343
Potassium, Week 12, n=270, 2764.21 ± 0.3054.19 ± 0.282
Potassium, Week 16, n=255, 2694.21 ± 0.2834.18 ± 0.303
Potassium, Week 20, n=260, 2724.21 ± 0.3204.19 ± 0.313
Potassium, Week 24, n=261, 2684.24 ± 0.3224.21 ± 0.312
Potassium, Week 28, n=253, 2684.20 ± 0.2984.23 ± 0.294
Potassium, Week 32, n=255, 2684.21 ± 0.2954.21 ± 0.315
Potassium, Week 36, n=254, 2614.21 ± 0.3144.22 ± 0.314
Potassium, Week 40, n=250, 2664.19 ± 0.3014.20 ± 0.305
Potassium, Week 44, n=258, 2634.21 ± 0.3024.21 ± 0.324
Potassium, Week 48, n=247, 2624.13 ± 0.2884.17 ± 0.449
Sodium, Baseline (Day 1), n=283, 283139.2 ± 1.89139.2 ± 1.76
Sodium, Week 4, n=280, 277139.5 ± 1.98139.4 ± 1.83
Sodium, Week 8, n=212, 278139.4 ± 1.78139.3 ± 1.86
Sodium, Week 12, n=270, 276139.5 ± 1.80139.3 ± 1.84
Sodium, Week 16, n=255, 269139.4 ± 1.76139.4 ± 1.94
Sodium, Week 20, n=260, 272139.4 ± 1.75139.5 ± 1.77
Sodium, Week 24, n=261, 268139.3 ± 1.82139.4 ± 1.95
Sodium, Week 28, n=253, 268139.4 ± 1.80139.5 ± 1.83
Sodium, Week 32, n=255, 268139.4 ± 1.83139.4 ± 1.72
Sodium, Week 36, n=254, 261139.3 ± 1.87139.5 ± 1.70
Sodium, Week 40, n=250, 266139.3 ± 2.04139.5 ± 1.84
Sodium, Week 44, n=258, 263139.5 ± 1.95139.6 ± 1.79
Sodium, Week 48, n=247, 262139.4 ± 1.68139.5 ± 1.75
Urea, Baseline (Day 1), n=283, 2835.30 ± 1.4685.17 ± 1.458
Urea, Week 4, n=280, 2775.33 ± 1.4245.14 ± 1.508
Urea, Week 8, n=212, 2785.32 ± 1.4855.12 ± 1.480
Urea, Week 12, n=270, 2765.28 ± 1.4245.20 ± 1.574
Urea, Week 16, n=255, 2695.26 ± 1.3855.20 ± 1.561
Urea, Week 20, n=260, 2725.18 ± 1.3495.22 ± 1.483
Urea, Week 24, n=261, 2685.38 ± 1.4895.11 ± 1.449
Urea, Week 28, n=253, 2685.32 ± 1.4225.21 ± 1.406
Urea, Week 32, n=255, 2685.43 ± 1.4405.17 ± 1.491
Urea, Week 36, n=254, 2615.31 ± 1.3965.23 ± 1.556
Urea, Week 40, n=250, 2665.40 ± 1.5235.26 ± 1.566
Urea, Week 44, n=258, 2635.38 ± 1.5435.24 ± 1.512
Urea, Week 48, n=247, 2625.37 ± 1.4025.27 ± 2.305
SecondaryAbsolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase

Blood samples were collected for the analysis of clinical chemistry parameter-lipase at indicated timepoints.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · Units per liter
Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase
Units per literCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Baseline (Day 1), n=283, 28331.0 ± 21.0430.9 ± 28.89
Week 4, n=278, 27631.7 ± 27.1732.6 ± 24.73
Week 8, n=211, 27831.5 ± 21.1531.3 ± 19.96
Week 12, n=270, 27631.4 ± 23.9433.6 ± 23.37
Week 16, n=254, 26930.8 ± 22.3932.1 ± 18.99
Week 20, n=260, 27031.3 ± 23.4631.9 ± 19.13
Week 24, n=260, 26831.3 ± 22.6032.2 ± 21.08
Week 28, n=253, 26830.3 ± 18.7133.0 ± 22.56
Week 32, n=254, 26833.5 ± 35.3833.2 ± 32.95
Week 36, n=254, 26131.5 ± 20.4931.2 ± 20.03
Week 40, n=250, 26632.6 ± 27.0732.1 ± 22.19
Week 44, n=258, 26336.3 ± 45.0433.0 ± 24.09
Week 48, n=247, 26130.1 ± 20.3132.6 ± 28.96
SecondaryAbsolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance.

Blood samples were collected for the analysis of clinical chemistry parameter-creatinine clearance at indicated timepoints. Glomerular filtration rate (GFR) will be estimated by the central laboratory using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI).

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · mL/min/1.73/m^2
Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance.
mL/min/1.73/m^2CAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Baseline (Day 1), n=283, 28394.3 ± 17.6197.9 ± 17.70
Week 4, n=278, 277101.2 ± 16.5696.5 ± 17.14
Week 8, n=211, 278104.9 ± 15.6498.1 ± 17.46
Week 12, n=270, 276104.8 ± 16.0898.6 ± 17.77
Week 16, n=254, 269104.2 ± 15.0397.6 ± 16.84
Week 20, n=261, 271105.5 ± 15.1998.0 ± 17.67
Week 24, n=261, 268105.1 ± 16.0597.9 ± 17.33
Week 28, n=253, 268105.3 ± 16.1898.8 ± 17.40
Week 32, n=254, 268105.1 ± 16.1098.8 ± 17.39
Week 36, n=254, 262104.7 ± 15.8898.0 ± 16.60
Week 40, n=250, 266104.3 ± 16.4798.3 ± 17.25
Week 44, n=258, 263104.4 ± 16.7398.9 ± 16.67
Week 48, n=247, 261103.6 ± 16.3496.9 ± 18.21
SecondaryAbsolute Values for Fasting Lipid Panel Overtime Including Week 48

Blood samples were collected at Baseline and at Week 48 to assess fasting lipids which included total cholesterol, high density lipoprotein (HDL)cholesterol, low density lipoprotein (LDL) cholesterol and triglycerides.

Time frame:
Baseline (Day 1) and at Week 48
Reported as:
Mean · Millimoles per liter
Absolute Values for Fasting Lipid Panel Overtime Including Week 48
Millimoles per literCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Total Cholesterol, Baseline (Day 1), n=268, 2754.44 ± 0.9284.42 ± 0.986
Total Cholesterol, Week 48, n=240, 2394.65 ± 1.0214.46 ± 0.944
HDL cholesterol, Baseline (Day 1), n=268, 2751.249 ± 0.37611.302 ± 0.3851
HDL cholesterol, Week 48, n=240, 2391.359 ± 0.40961.376 ± 0.4335
LDL cholesterol, Baseline (Day 1), n=267, 2752.557 ± 0.79912.529 ± 0.7870
LDL cholesterol, Week 48, n=238, 2372.697 ± 0.91582.472 ± 0.7693
Triglycerides, Baseline (Day 1), n=268, 2751.387 ± 0.91421.294 ± 0.7392
Triglycerides, Week 48, n=240, 2391.323 ± 0.93331.341 ± 0.9059
SecondaryNumber of Participants With Abnormal Urinalysis Parameter Over Time Including Week 48

The dipstick test gives results in a semi-quantitative manner and results for urinalysis parameters (ketones, glucose, bilirubin, occult blood, nitrite and blood protein) can be read as positive, trace, 1+, 2+, 3+ and 4+ indicating proportional concentrations in the urine sample. The urine parameters were graded according to DAIDS scale where Grade 1 indicates mild (trace to 1+), Grade 2 indicates moderate (2+) and Grade 3 indicates severe (3+ or higher). Only participants with abnormal findings for urinalysis at any visit has been presented.

Time frame:
Baseline (Day 1) and at Weeks 4, 24 and 48
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Urinalysis Parameter Over Time Including Week 48
ParticipantsCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Urine bilirubin,Baseline (Day 1),Trace, n=276, 27600
Urine bilirubin, Baseline (Day 1), 1+, n=276, 2761522
Urine bilirubin, Baseline (Day 1), 2+, n=276, 27601
Urine bilirubin, Baseline (Day 1), 3+, n=276, 27600
Urine glucose, Baseline (Day 1), Trace, n=282, 28201
Urine glucose, Baseline (Day 1), 1+, n=282, 28220
Urine glucose, Baseline (Day 1), 2+, n=282, 28200
Urine glucose, Baseline (Day 1), 3+, n=282, 28211
Urine ketones, Baseline (Day 1), Trace, n=276, 2763029
Urine ketones, Baseline (Day 1), 1+, n=276, 27642
Urine ketones, Baseline (Day 1), 2+, n=276, 27601
Urine ketones, Baseline (Day 1), 3+, n=276, 27600
Urine leukocyte esterase,Baseline,Trace,n=276, 2762221
Urine leukocyte esterase, Baseline, 1+, n=276, 2761214
Urine leukocyte esterase, Baseline, 2+, n=276, 27699
Urine leukocyte esterase, Baseline, 3+, n=276, 27633
Urine nitrite, Baseline, positive, n=276, 27669
Urine occult blood, Baseline, Trace, n=276, 276139
Urine occult blood, Baseline, 1+, n=276, 27656
Urine occult blood, Baseline, 2+, n=276, 27663
Urine occult blood, Baseline, 3+, n=276, 27632
Urine protein, Baseline, Trace, n=276, 2762520
Urine protein, Baseline, 1+, n=276, 276410
Urine protein, Baseline, 2+, n=276, 27637
Urine protein, Baseline, 3+, n=276, 27600
Urine bilirubin, Week 4, Trace, n=278, 27200
Urine bilirubin, Week 4, 1+, n=278, 2721428
Urine bilirubin, Week 4, 2+, n=278, 27200
Urine bilirubin, Week 4, 3+, n=278, 27200
Urine glucose, Week 4, Trace, n=278, 27200
Urine glucose, Week 4, 1+, n=278, 27202
Urine glucose, Week 4, 2+, n=278, 27200
Urine glucose, Week 4, 3+, n=278, 27210
Urine ketones, Week 4, Trace, n=278, 2722021
Urine ketones, Week 4, 1+, n=278, 27215
Urine ketones, Week 4, 2+, n=278, 27200
Urine ketones, Week 4, 3+, n=278, 27210
Urine leukocyte esterase, Week 4, Trace,n=278, 2721923
Urine leukocyte esterase, Week 4, 1+, n=278, 272917
Urine leukocyte esterase, Week 4, 2+, n=278, 27266
Urine leukocyte esterase, Week 4, 3+, n=278, 27224
Urine nitrite, Week 4, positive, n=278, 272210
Urine occult blood, Week 4, Trace, n=278, 2721113
Urine occult blood, Week 4, 1+, n=278, 27283
Urine occult blood, Week 4, 2+, n=278, 27251
Urine occult blood, Week 4, 3+, n=278, 27206
Urine protein, Week 4, Trace, n=278, 2721224
Urine protein, Week 4, 1+, n=278, 272411
Urine protein, Week 4, 2+, n=278, 27213
Urine protein, Week 4, 3+, n=278, 27211
Urine bilirubin, Week 24, Trace, n=195, 25800
Urine bilirubin, Week 24, 1+, n=195, 258714
, Urine bilirubin, Week 24, 2+, n=195, 25800
Urine bilirubin, Week 24, 3+, n=195, 25800
Urine glucose, Week 24, Trace, n=195, 25800
Urine glucose, Week 24, 1+, n=195, 25800
Urine glucose, Week 24, 2+, n=195, 25810
Urine glucose, Week 24, 3+, n=195, 25811
Urine ketones, Week 24, Trace, n=195, 258139
Urine ketones, Week 24, 1+, n=195, 25802
Urine ketones, Week 24, 2+, n=195, 25800
Urine ketones, Week 24, 3+, n=195, 25800
Urine leukocyte esterase,Week 24, Trace,n=195, 2581528
Urine leukocyte esterase, Week 24, 1+, n=195, 258812
Urine leukocyte esterase, Week 24, 2+, n=195, 258310
Urine leukocyte esterase, Week 24, 3+, n=195, 25813
Urine nitrite, Week 24, positive, n=195, 25845
Urine occult blood, Week 24, Trace, n=195, 25899
Urine occult blood, Week 24, 1+, n=195, 25838
Urine occult blood, Week 24, 2+, n=195, 25832
Urine occult blood, Week 24, 3+, n=195, 25813
Urine protein, Week 24, Trace, n=195, 2581121
Urine protein, Week 24, 1+, n=195, 25847
Urine protein, Week 24, 2+, n=195, 25824
Urine protein, Week 24, 3+, n=195, 25801
Urine bilirubin, Week 48, Trace, n=261, 25900
Urine bilirubin, Week 48, 1+, n=261, 259912
Urine bilirubin, Week 48, 2+, n=261, 25900
Urine bilirubin, Week 48, 3+, n=261, 25901
Urine glucose, Week 48, Trace, n=261, 25900
Urine glucose, Week 48, 1+, n=261, 25910
Urine glucose, Week 48, 2+, n=261, 25900
Urine glucose, Week 48, 3+, n=261, 25920
Urine ketones, Week 48, Trace, n=261, 2591213
Urine ketones, Week 48, 1+, n=261, 25904
Urine ketones, Week 48, 2+, n=261, 25900
Urine ketones, Week 48, 3+, n=261, 25900
Urine leukocyte esterase, Week 48,Trace,n=261, 2591215
Urine leukocyte esterase, Week 48, 1+, n=261, 259510
Urine leukocyte esterase, Week 48, 2+, n=261, 25947
Urine leukocyte esterase, Week 48, 3+, n=261, 25922
Urine nitrite, Week 48, positive, n=261, 25926
Urine occult blood, Week 48, Trace, n=261, 25998
Urine occult blood, Week 48, 1+, n=261, 25946
Urine occult blood, Week 48, 2+, n=261, 25983
Urine occult blood, Week 48, 3+, n=261, 25910
Urine protein, Week 48, Trace, n=261, 2591423
Urine protein, Week 48, 1+, n=261, 25958
Urine protein, Week 48, 2+, n=261, 25966
Urine protein, Week 48, 3+, n=261, 25900
SecondaryNumber of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48

Urine samples were collected for analysis of urine pH. pH is calculated on a scale of 0 to 14, values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH of less than 7 is acidic and a pH of greater than 7 is basic. Normal urine has a slightly acidic pH (5.0-6.0).

Time frame:
Baseline (Day 1) and at Weeks 4, 24 and 48
Reported as:
Count of participants · Participants
Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48
ParticipantsCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Baseline (Day 1), pH=5, n=276, 2763632
Baseline (Day 1), pH=5.5, n=276, 276104101
Baseline (Day 1), pH=6, n=276, 2766662
Baseline (Day 1), pH=6.5, n=276, 2762935
Baseline (Day 1), pH=7, n=276, 2762727
Baseline (Day 1), pH=7.5, n=276, 276712
Baseline (Day 1), pH=8, n=276, 27644
Baseline (Day 1), pH=8.5, n=276, 27621
Baseline (Day 1), pH>9.0, n=276, 27612
Week 4, pH=5, n=278, 2723341
Week 4, pH=5.5, n=278, 2728381
Week 4, pH=6, n=278, 2726871
Week 4, pH=6.5, n=278, 2724836
Week 4, pH=7, n=278, 2722522
Week 4, pH=7.5, n=278, 2721012
Week 4, pH=8, n=278, 27255
Week 4, pH=8.5, n=278, 27261
Week 4, pH>9.0, n=278, 27203
Week 24, pH=5, n=195, 2584250
Week 24, pH=5.5, n=195, 2585578
Week 24, pH=6, n=195, 2584751
Week 24, pH=6.5, n=195, 2581946
Week 24, pH=7, n=195, 2582216
Week 24, pH=7.5, n=195, 258413
Week 24, pH=8, n=195, 25832
Week 24, pH=8.5, n=195, 25831
Week 24, pH>9.0, n=195, 25801
Week 48, pH=5, n=261, 2595457
Week 48, pH=5.5, n=261, 2598177
Week 48, pH=6, n=261, 2595061
Week 48, pH=6.5, n=261, 2593027
Week 48, pH=7, n=261, 2592418
Week 48, pH=7.5, n=261, 2591410
Week 48, pH=8, n=261, 25954
Week 48, pH=8.5, n=261, 25923
Week 48, pH>9.0, n=261, 25912
SecondaryChange From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets

Blood samples were collected for the analysis of hematology parameters including basophil, eosinophils, leukocytes, lymphocytes, neutrophils, monocytes, and platelets at indicated timepoints. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline was defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · 10^9 cells per Liter
Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets
10^9 cells per LiterCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Basophils, Week 4, n=277, 2700.002 ± 0.01550.002 ± 0.0155
Basophils, Week 8, n=210, 2720.002 ± 0.01610.001 ± 0.0153
Basophils, Week 12, n=267, 2720.003 ± 0.01810.001 ± 0.0157
Basophils, Week 16, n=247, 2590.008 ± 0.02150.006 ± 0.0227
Basophils, Week 20, n=247, 2590.013 ± 0.02500.010 ± 0.0271
Basophils, Week 24, n=256, 2600.015 ± 0.02470.014 ± 0.0269
Basophils, Week 28, n=239, 2580.017 ± 0.02650.016 ± 0.0251
Basophils, Week 32, n=246, 2630.022 ± 0.02660.017 ± 0.0227
Basophils, Week 36, n=250, 2590.021 ± 0.02350.018 ± 0.0249
Basophils, Week 40, n=244, 2450.020 ± 0.02520.019 ± 0.0243
Basophils, Week 44, n=249, 2600.018 ± 0.02460.018 ± 0.0265
Basophils, Week 48, n=239, 2580.016 ± 0.02180.016 ± 0.0243
Eosinophils, Week 4, n=277, 2700.024 ± 0.10990.013 ± 0.1220
Eosinophils, Week 8, n=210, 2720.023 ± 0.11010.009 ± 0.1075
Eosinophils, Week 12, n=267, 2720.023 ± 0.13050.018 ± 0.1082
Eosinophils, Week 16, n=247, 2590.037 ± 0.14250.022 ± 0.1262
Eosinophils, Week 20, n=247, 2590.044 ± 0.14780.027 ± 0.1288
Eosinophils, Week 24, n=256, 2600.051 ± 0.13070.030 ± 0.1124
Eosinophils, Week 28, n=239, 2580.061 ± 0.13670.037 ± 0.1393
Eosinophils, Week 32, n=246, 2630.061 ± 0.15560.029 ± 0.1158
Eosinophils, Week 36, n=250, 2590.070 ± 0.17970.030 ± 0.1303
Eosinophils, Week 40, n=244, 2450.062 ± 0.16230.035 ± 0.1155
Eosinophils, Week 44, n=249, 2600.057 ± 0.15980.038 ± 0.1410
Eosinophils, Week 48, n=239, 2580.039 ± 0.14160.030 ± 0.1183
Leukocytes, Week 4, n=279, 2720.57 ± 1.4040.42 ± 1.383
Leukocytes, Week 8, n=211, 2750.18 ± 1.2780.32 ± 1.374
Leukocytes, Week 12, n=270, 2750.07 ± 1.4020.40 ± 1.465
Leukocytes, Week 16, n=252, 2650.32 ± 1.6410.41 ± 1.621
Leukocytes, Week 20, n=254, 2650.27 ± 1.5050.44 ± 1.480
Leukocytes, Week 24, n=258, 2640.34 ± 1.5810.45 ± 1.725
Leukocytes, Week 28, n=244, 2630.34 ± 1.7130.48 ± 1.551
Leukocytes, Week 32, n=253, 2660.28 ± 1.7260.42 ± 1.748
Leukocytes, Week 36, n=252, 2590.34 ± 1.5490.52 ± 1.789
Leukocytes, Week 40, n=246, 2530.16 ± 1.4970.42 ± 1.614
Leukocytes, Week 44, n=256, 2620.22 ± 1.7320.49 ± 1.626
Leukocytes, Week 48, n=243, 2600.09 ± 1.4550.29 ± 1.520
Lymphocytes, Week 4, n=277, 2700.198 ± 0.51560.231 ± 0.5066
Lymphocytes, Week 8, n=210, 2720.054 ± 0.48120.155 ± 0.5088
Lymphocytes, Week 12, n=267, 2720.012 ± 0.46320.164 ± 0.5560
Lymphocytes, Week 16, n=247, 2590.020 ± 0.49710.158 ± 0.5246
Lymphocytes, Week 20, n=247, 2590.030 ± 0.48890.146 ± 0.5292
Lymphocytes, Week 24, n=256, 2600.014 ± 0.51950.148 ± 0.5716
Lymphocytes, Week 28, n=239, 2580.021 ± 0.53890.145 ± 0.5469
Lymphocytes, Week 32, n=246, 2630.021 ± 0.51950.129 ± 0.5812
Lymphocytes, Week 36, n=250, 2590.028 ± 0.52610.132 ± 0.5258
Lymphocytes, Week 40, n=244, 2450.006 ± 0.53030.054 ± 0.5106
Lymphocytes, Week 44, n=249, 260-0.021 ± 0.61760.098 ± 0.5139
Lymphocytes, Week 48, n=239, 258-0.074 ± 0.51910.039 ± 0.5936
Monocytes, Week 4, n=277, 2700.038 ± 0.12690.031 ± 0.1528
Monocytes, Week 8, n=210, 2720.022 ± 0.14640.013 ± 0.1600
Monocytes, Week 12, n=267, 2720.016 ± 0.12340.018 ± 0.1613
Monocytes, Week 16, n=247, 2590.059 ± 0.15480.035 ± 0.1618
Monocytes, Week 20, n=247, 2590.070 ± 0.15830.053 ± 0.1790
Monocytes, Week 24, n=256, 2600.059 ± 0.14420.070 ± 0.1599
Monocytes, Week 28, n=239, 2580.086 ± 0.15840.077 ± 0.1806
Monocytes, Week 32, n=246, 2630.081 ± 0.15300.088 ± 0.1841
Monocytes, Week 36, n=250, 2590.084 ± 0.16850.086 ± 0.1772
Monocytes, Week 40, n=244, 2450.056 ± 0.13780.076 ± 0.1651
Monocytes, Week 44, n=249, 2600.062 ± 0.15220.057 ± 0.1558
Monocytes, Week 48, n=239, 2580.024 ± 0.13950.031 ± 0.1389
Neutrophils, Week 4, n=277, 2700.313 ± 1.35080.130 ± 1.1869
Neutrophils, Week 8, n=210, 2720.084 ± 1.13100.125 ± 1.2775
Neutrophils, Week 12, n=267, 2720.032 ± 1.30160.185 ± 1.3016
Neutrophils, Week 16, n=247, 2590.215 ± 1.57520.211 ± 1.4233
Neutrophils, Week 20, n=247, 2590.132 ± 1.41160.217 ± 1.3130
Neutrophils, Week 24, n=256, 2600.218 ± 1.48900.217 ± 1.4694
Neutrophils, Week 28, n=239, 2580.193 ± 1.58330.221 ± 1.3274
Neutrophils, Week 32, n=246, 2630.144 ± 1.57390.175 ± 1.5009
Neutrophils, Week 36, n=250, 2590.170 ± 1.38650.243 ± 1.4938
Neutrophils, Week 40, n=244, 2450.055 ± 1.43720.259 ± 1.4739
Neutrophils, Week 44, n=249, 2600.156 ± 1.53820.273 ± 1.4445
Neutrophils, Week 48, n=239, 2580.110 ± 1.36970.201 ± 1.3169
Platelets, Week 4, n=278, 2695.7 ± 29.104.3 ± 31.11
Platelets, Week 8, n=207, 273-0.9 ± 29.092.2 ± 35.14
Platelets, Week 12, n=269, 2710.8 ± 32.496.2 ± 36.23
Platelets, Week 16, n=251, 2631.6 ± 33.349.3 ± 51.53
Platelets, Week 20, n=255, 2647.6 ± 38.1813.4 ± 39.24
Platelets, Week 24, n=256, 2616.5 ± 36.1114.4 ± 35.15
Platelets, Week 28, n=245, 2588.6 ± 38.2318.4 ± 38.56
Platelets, Week 32, n=249, 2627.9 ± 40.2214.6 ± 34.28
Platelets, Week 36, n=248, 25912.1 ± 38.4818.6 ± 35.81
Platelets, Week 40, n=244, 2548.2 ± 36.0817.7 ± 43.30
Platelets, Week 44, n=254, 2619.4 ± 38.4219.3 ± 47.64
Platelets, Week 48, n=240, 2557.7 ± 39.6116.4 ± 47.45
SecondaryChange From Baseline for Hematology Parameters: Erythrocyte Mean Corpuscular Volume

Blood samples were collected for the analysis of hematology parameter including erythrocyte mean corpuscular volume at indicated timepoints. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance phase dose of IP. Change from Baseline was defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · Femtoliters
Change From Baseline for Hematology Parameters: Erythrocyte Mean Corpuscular Volume
FemtolitersCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Week 4, n=279, 273-0.7 ± 1.660.2 ± 1.56
Week 8, n=211, 275-2.5 ± 2.330.2 ± 2.06
Week 12, n=270, 275-3.8 ± 2.49-0.3 ± 2.48
Week 16, n=254, 265-5.1 ± 2.63-0.2 ± 2.65
Week 20, n=255, 267-5.6 ± 2.72-0.5 ± 2.55
Week 24, n=259, 264-5.6 ± 2.85-0.5 ± 2.58
Week 28, n=246, 265-5.6 ± 2.97-0.9 ± 2.52
Week 32, n=254, 267-5.3 ± 3.02-0.9 ± 2.55
Week 36, n=252, 261-5.3 ± 3.00-0.6 ± 2.45
Week 40, n=246, 255-4.8 ± 3.02-0.1 ± 2.64
Week 44, n=256, 262-4.2 ± 3.120.2 ± 2.81
Week 48, n=243, 260-3.7 ± 3.121.0 ± 2.93
SecondaryChange From Baseline for Hematology Parameters: Erythrocytes

Blood samples were collected for the analysis of hematology parameters including erythrocytes at indicated timepoints. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance phase dose of IP. Change from Baseline was defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · 10^12 cells per Liter
Change From Baseline for Hematology Parameters: Erythrocytes
10^12 cells per LiterCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Week 4, n=279, 2730.08 ± 0.226-0.03 ± 0.228
Week 8, n=211, 2750.18 ± 0.2490.02 ± 0.239
Week 12, n=270, 2750.23 ± 0.2690.01 ± 0.273
Week 16, n=254, 2650.30 ± 0.2630.01 ± 0.255
Week 20, n=255, 2670.31 ± 0.272-0.01 ± 0.242
Week 24, n=259, 2640.31 ± 0.2540.02 ± 0.242
Week 28, n=246, 2650.29 ± 0.2480.04 ± 0.259
Week 32, n=254, 2670.25 ± 0.2830.01 ± 0.259
Week 36, n=252, 2610.23 ± 0.263-0.01 ± 0.250
Week 40, n=246, 2550.23 ± 0.246-0.01 ± 0.239
Week 44, n=256, 2620.21 ± 0.234-0.06 ± 0.243
Week 48, n=243, 2600.16 ± 0.264-0.06 ± 0.257
SecondaryChange From Baseline for Hematology Parameters: Hematocrit

Blood samples were collected for the analysis of hematology parameters including hematocrit at indicated timepoints. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance phase dose of IP. Change from Baseline was defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · Proportion of red blood cells in blood
Change From Baseline for Hematology Parameters: Hematocrit
Proportion of red blood cells in bloodCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Week 4, n=279, 2730.0046 ± 0.02082-0.0013 ± 0.02213
Week 8, n=211, 2750.0053 ± 0.023440.0026 ± 0.02314
Week 12, n=270, 2750.0040 ± 0.02383-0.0000 ± 0.02618
Week 16, n=254, 2650.0035 ± 0.02338-0.0003 ± 0.02489
Week 20, n=255, 2670.0024 ± 0.02335-0.0033 ± 0.02323
Week 24, n=259, 2640.0021 ± 0.02299-0.0012 ± 0.02337
Week 28, n=246, 265-0.0003 ± 0.02262-0.0001 ± 0.02460
Week 32, n=254, 267-0.0017 ± 0.02607-0.0032 ± 0.02503
Week 36, n=252, 261-0.0041 ± 0.02515-0.0032 ± 0.02407
Week 40, n=246, 255-0.0014 ± 0.02461-0.0017 ± 0.02388
Week 44, n=256, 262-0.0011 ± 0.02230-0.0045 ± 0.02328
Week 48, n=243, 260-0.0027 ± 0.02571-0.0019 ± 0.02572
SecondaryChange From Baseline for Hematology Parameters: Hemoglobin

Blood samples were collected for the analysis of hematology parameter including hemoglobin at indicated timepoints. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · Grams per liter
Change From Baseline for Hematology Parameters: Hemoglobin
Grams per literCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Week 4, n=279, 2731.8 ± 6.590.1 ± 6.47
Week 8, n=211, 2751.9 ± 7.291.3 ± 7.26
Week 12, n=270, 2752.1 ± 7.471.5 ± 8.28
Week 16, n=254, 2652.9 ± 6.981.4 ± 7.88
Week 20, n=255, 2672.9 ± 7.431.4 ± 7.18
Week 24, n=259, 2642.7 ± 7.322.0 ± 7.11
Week 28, n=246, 2652.7 ± 6.803.3 ± 7.75
Week 32, n=254, 2672.7 ± 8.082.9 ± 7.73
Week 36, n=252, 2612.0 ± 7.932.8 ± 7.73
Week 40, n=246, 2553.2 ± 7.913.1 ± 7.85
Week 44, n=256, 2622.5 ± 7.661.8 ± 7.62
Week 48, n=243, 2601.4 ± 7.982.1 ± 8.33
SecondaryChange From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK

Blood samples were collected for the analysis of clinical chemistry parameters including ALT, ALP, AST and CK. Baseline values is defined as the latest pre-treatment assessment with a non-missing value. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · International units per liter
Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK
International units per literCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
ALT, Week 4, n=281, 2773.7 ± 49.90-1.4 ± 11.14
ALT, Week 8, n=212, 2781.0 ± 14.28-0.9 ± 11.86
ALT, Week 12, n=270, 2761.0 ± 15.80-0.1 ± 13.27
ALT, Week 16, n=255, 2691.2 ± 16.611.5 ± 13.99
ALT, Week 20, n=260, 2725.3 ± 72.800.2 ± 17.04
ALT, Week 24, n=261, 2683.3 ± 30.00-0.4 ± 12.75
ALT, Week 28, n=253, 2681.9 ± 18.820.2 ± 12.72
ALT, Week 32, n=256, 26818.1 ± 293.85-0.4 ± 13.08
ALT, Week 36, n=255, 261-0.1 ± 14.101.7 ± 32.63
ALT, Week 40, n=250, 2660.6 ± 17.420.0 ± 14.84
ALT, Week 44, n=258, 2631.7 ± 27.550.8 ± 16.75
ALT, Week 48, n=247, 262-0.2 ± 22.910.1 ± 18.81
ALP, Week 4, n=281, 2770.3 ± 11.04-1.3 ± 15.74
ALP, Week 8, n=212, 2780.6 ± 10.41-0.5 ± 17.00
ALP, Week 12, n=270, 2761.4 ± 12.71-0.7 ± 17.40
ALP, Week 16, n=255, 2690.8 ± 10.34-0.3 ± 17.99
ALP, Week 20, n=260, 2721.5 ± 10.20-1.1 ± 17.35
ALP, Week 24, n=261, 2681.2 ± 9.57-0.7 ± 17.03
ALP, Week 28, n=253, 2681.4 ± 10.570.6 ± 17.28
ALP, Week 32, n=256, 2681.9 ± 15.42-0.3 ± 18.11
ALP, Week 36, n=255, 2613.3 ± 20.311.3 ± 20.90
ALP, Week 40, n=250, 2661.8 ± 9.840.7 ± 18.50
ALP, Week 44, n=258, 2631.4 ± 11.001.2 ± 17.62
ALP, Week 48, n=247, 2621.1 ± 12.750.7 ± 17.54
AST, Week 4, n=281, 2771.5 ± 24.47-1.6 ± 14.58
AST, Week 8, n=212, 2780.7 ± 19.90-2.0 ± 14.13
AST, Week 12, n=270, 276-0.3 ± 10.74-1.5 ± 15.34
AST, Week 16, n=255, 269-0.1 ± 11.311.0 ± 16.68
AST, Week 20, n=260, 2722.3 ± 32.280.2 ± 26.46
AST, Week 24, n=261, 2682.8 ± 24.22-1.5 ± 16.00
AST, Week 28, n=253, 2681.7 ± 15.85-0.9 ± 16.99
AST, Week 32, n=256, 26814.0 ± 233.48-1.9 ± 14.68
AST, Week 36, n=255, 261-0.1 ± 12.22-0.2 ± 22.03
AST, Week 40, n=250, 2660.2 ± 13.31-1.5 ± 15.24
AST, Week 44, n=258, 2631.3 ± 16.49-0.5 ± 18.31
AST Week 48, n=247, 262-0.8 ± 11.880.8 ± 44.70
CK, Week 4, n=280, 27731.1 ± 456.63-27.0 ± 523.89
CK, Week 8, n=212, 27853.5 ± 907.83-46.6 ± 499.91
CK, Week 12, n=270, 2761.2 ± 420.32-17.2 ± 605.92
CK, Week 16, n=255, 269-18.0 ± 316.7440.2 ± 746.32
CK, Week 20, n=260, 27219.2 ± 536.7057.3 ± 1208.73
CK, Week 24, n=261, 26847.3 ± 635.42-19.6 ± 605.13
CK, Week 28, n=253, 26849.9 ± 669.37-8.5 ± 705.35
CK, Week 32, n=256, 268-24.5 ± 298.70-42.5 ± 509.77
CK, Week 36, n=254, 26114.7 ± 515.6212.2 ± 674.76
CK, Week 40, n=250, 26624.8 ± 544.72-51.7 ± 497.70
CK, Week 44, n=258, 26354.8 ± 526.28-20.1 ± 652.24
CK, Week 48, n=247, 262-17.8 ± 309.33121.1 ± 2682.33
SecondaryChange From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin

Blood samples were collected for the analysis of clinical chemistry parameter-albumin. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · Grams per liter
Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin
Grams per literCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Week 4, n=280, 277-0.1 ± 2.15-0.3 ± 2.14
Week 8, n=212, 278-0.1 ± 2.32-0.3 ± 2.25
Week 12, n=270, 276-0.1 ± 2.380.0 ± 2.58
Week 16, n=255, 2690.2 ± 2.23-0.1 ± 2.48
Week 20, n=260, 2720.2 ± 2.51-0.2 ± 2.47
Week 24, n=261, 2680.5 ± 2.280.2 ± 2.37
Week 28, n=253, 2680.5 ± 2.420.4 ± 2.32
Week 32, n=255, 2680.7 ± 2.470.4 ± 2.60
Week 36, n=254, 2610.3 ± 2.440.3 ± 2.52
Week 40, n=250, 2660.9 ± 2.420.5 ± 2.46
Week 44, n=258, 2630.9 ± 2.440.4 ± 2.49
Week 48, n=247, 2620.7 ± 2.400.5 ± 2.63
SecondaryChange From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine

Blood samples were collected for the analysis of clinical chemistry parameters including bilirubin, creatinine and direct bilirubin. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · Micromoles per liter
Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine
Micromoles per literCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Bilirubin, Week 4, n=281, 2771.4 ± 4.74-0.3 ± 3.77
Bilirubin, Week 8, n=212, 2780.9 ± 4.04-0.5 ± 4.17
Bilirubin, Week 12, n=270, 2761.2 ± 4.15-0.7 ± 4.51
Bilirubin, Week 16, n=255, 2691.2 ± 4.30-0.3 ± 3.61
Bilirubin, Week 20, n=260, 2721.1 ± 4.14-0.7 ± 4.02
Bilirubin, Week 24, n=261, 2680.8 ± 4.12-0.4 ± 3.85
Bilirubin, Week 28, n=253, 2681.2 ± 4.41-0.7 ± 3.75
Bilirubin, Week 32, n=256, 2681.3 ± 6.44-0.6 ± 4.05
Bilirubin, Week 36, n=255, 2600.6 ± 5.36-0.7 ± 4.28
Bilirubin, Week 40, n=250, 2660.9 ± 4.31-0.8 ± 4.32
Bilirubin, Week 44, n=258, 2631.2 ± 4.34-0.4 ± 4.28
Bilirubin, Week 48, n=247, 2621.1 ± 4.18-0.3 ± 4.17
Direct bilirubin, Week 4, n=277, 2770.2 ± 1.40-0.1 ± 1.33
Direct bilirubin, Week 8, n=212, 2780.2 ± 1.30-0.1 ± 1.19
Direct bilirubin, Week 12, n=269, 2730.2 ± 1.220.0 ± 1.22
Direct bilirubin, Week 16, n=254, 2680.2 ± 1.44-0.1 ± 1.14
Direct bilirubin, Week 20, n=260, 2720.2 ± 1.57-0.1 ± 1.14
Direct bilirubin, Week 24, n=260, 2660.1 ± 1.46-0.1 ± 1.10
Direct bilirubin, Week 28, n=253, 2680.2 ± 1.26-0.1 ± 1.22
Direct bilirubin, Week 32, n=256, 2680.3 ± 3.39-0.1 ± 1.08
Direct bilirubin, Week 36, n=255, 2600.1 ± 2.18-0.1 ± 1.16
Direct bilirubin, Week 40, n=249, 2660.1 ± 1.42-0.1 ± 1.26
Direct bilirubin, Week 44, n=258, 2630.2 ± 1.41-0.1 ± 1.19
Direct bilirubin, Week 48, n=247, 2620.0 ± 1.410.0 ± 1.19
Creatinine, Week 4, n=280, 277-6.07 ± 9.6960.61 ± 7.635
Creatinine, Week 8, n=212, 278-9.25 ± 9.936-0.24 ± 8.838
Creatinine, Week 12, n=270, 276-9.89 ± 9.703-1.20 ± 8.710
Creatinine, Week 16, n=255, 269-9.75 ± 9.572-0.33 ± 8.964
Creatinine, Week 20, n=261, 272-10.10 ± 9.839-0.68 ± 8.700
Creatinine, Week 24, n=262, 268-9.73 ± 9.499-0.75 ± 8.327
Creatinine, Week 28, n=253, 268-10.34 ± 9.731-1.33 ± 8.892
Creatinine, Week 32, n=255, 268-9.77 ± 9.166-1.26 ± 9.243
Creatinine, Week 36, n=254, 262-9.57 ± 9.712-0.74 ± 8.565
Creatinine, Week 40, n=250, 266-9.60 ± 10.656-1.10 ± 7.875
Creatinine, Week 44, n=258, 263-9.02 ± 9.562-1.91 ± 8.306
Creatinine, Week 48, n=247, 262-8.97 ± 9.7425.00 ± 85.535
SecondaryChange From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48

Blood samples were collected for the analysis of clinical chemistry parameters which includes total CO2, chloride, glucose, phosphate, potassium, sodium and urea. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · Millimoles per liter
Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48
Millimoles per literCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
CO2, Week 4, n=280, 2760.6 ± 2.670.2 ± 2.32
CO2, Week 8, n=212, 2780.2 ± 2.51-0.1 ± 2.24
CO2, Week 12, n=270, 2760.2 ± 2.56-0.1 ± 2.26
CO2, Week 16, n=255, 2690.4 ± 2.55-0.1 ± 2.72
CO2, Week 20, n=260, 2720.3 ± 2.520.1 ± 2.38
CO2, Week 24, n=261, 2680.6 ± 2.840.4 ± 2.56
CO2, Week 28, n=253, 2680.5 ± 2.510.4 ± 2.39
CO2, Week 32, n=255, 2680.5 ± 2.720.3 ± 2.37
CO2, Week 36, n=253, 2610.7 ± 2.540.2 ± 2.35
CO2, Week 40, n=249, 2650.4 ± 2.530.2 ± 2.61
CO2, Week 44, n=257, 2630.4 ± 2.710.1 ± 2.37
CO2, Week 48, n=247, 2620.0 ± 2.700.0 ± 2.27
Chloride, Week 4, n=280, 2770.0 ± 2.130.5 ± 2.17
Chloride, Week 8, n=212, 2780.0 ± 2.050.3 ± 2.14
Chloride, Week 12, n=270, 2760.0 ± 2.100.4 ± 2.16
Chloride, Week 16, n=255, 269-0.2 ± 2.320.3 ± 2.39
Chloride, Week 20, n=260, 272-0.3 ± 2.490.4 ± 2.15
Chloride, Week 24, n=261, 268-0.2 ± 2.400.2 ± 2.47
Chloride, Week 28, n=253, 268-0.2 ± 2.210.1 ± 2.18
Chloride, Week 32, n=255, 268-0.2 ± 2.370.3 ± 2.34
Chloride, Week 36, n=254, 261-0.1 ± 2.460.4 ± 2.37
Chloride, Week 40, n=250, 2660.1 ± 2.350.4 ± 2.20
Chloride, Week 44, n=258, 2630.1 ± 2.400.7 ± 2.23
Chloride, Week 48, n=247, 2620.0 ± 2.230.3 ± 2.09
Phosphate, Week 4, n=279, 2770.032 ± 0.18650.014 ± 0.1771
Phosphate, Week 8, n=212, 278-0.016 ± 0.18340.017 ± 0.1855
Phosphate, Week 12, n=270, 276-0.010 ± 0.18250.009 ± 0.1772
Phosphate, Week 16, n=255, 2690.000 ± 0.17890.017 ± 0.1892
Phosphate, Week 20, n=260, 272-0.029 ± 0.19320.016 ± 0.1764
Phosphate, Week 24, n=261, 268-0.001 ± 0.19070.011 ± 0.1852
Phosphate, Week 28, n=253, 268-0.007 ± 0.18940.019 ± 0.1882
Phosphate, Week 32, n=255, 268-0.004 ± 0.18060.005 ± 0.2092
Phosphate, Week 36, n=254, 261-0.006 ± 0.17980.021 ± 0.1965
Phosphate, Week 40, n=250, 266-0.011 ± 0.18510.015 ± 0.1753
Phosphate, Week 44, n=258, 263-0.004 ± 0.18240.020 ± 0.1801
Phosphate, Week 48, n=247, 262-0.007 ± 0.17840.020 ± 0.2333
Potassium, Week 4, n=280, 2770.15 ± 0.3340.06 ± 0.368
Potassium, Week 8, n=212, 2780.10 ± 0.3480.08 ± 0.346
Potassium, Week 12, n=270, 2760.09 ± 0.3520.05 ± 0.305
Potassium, Week 16, n=255, 2690.10 ± 0.3210.04 ± 0.314
Potassium, Week 20, n=260, 2720.09 ± 0.3740.04 ± 0.364
Potassium, Week 24, n=261, 2680.12 ± 0.3530.07 ± 0.309
Potassium, Week 28, n=253, 2680.08 ± 0.3410.08 ± 0.350
Potassium, Week 32, n=255, 2680.09 ± 0.3340.06 ± 0.345
Potassium, Week 36, n=254, 2610.10 ± 0.3530.08 ± 0.347
Potassium, Week 40, n=250, 2660.07 ± 0.3470.06 ± 0.345
Potassium, Week 44, n=258, 2630.08 ± 0.3530.06 ± 0.338
Potassium, Week 48, n=247, 2620.01 ± 0.3430.03 ± 0.496
Sodium, Week 4, n=280, 2770.3 ± 2.250.2 ± 1.95
Sodium, Week 8, n=212, 2780.1 ± 1.980.1 ± 1.92
Sodium, Week 12, n=270, 2760.3 ± 1.840.1 ± 1.89
Sodium, Week 16, n=255, 2690.2 ± 2.100.3 ± 2.21
Sodium, Week 20, n=260, 2720.2 ± 2.080.4 ± 1.79
Sodium, Week 24, n=261, 2680.2 ± 2.020.2 ± 2.12
Sodium, Week 28, n=253, 2680.2 ± 1.880.4 ± 1.82
Sodium, Week 32, n=255, 2680.3 ± 2.130.3 ± 2.02
Sodium, Week 36, n=254, 2610.2 ± 2.160.4 ± 1.94
Sodium, Week 40, n=250, 2660.1 ± 2.080.4 ± 2.13
Sodium, Week 44, n=258, 2630.3 ± 2.300.4 ± 2.01
Sodium, Week 48, n=247, 2620.2 ± 2.110.3 ± 1.72
Urea, Week 4, n=280, 2770.04 ± 1.292-0.05 ± 1.240
Urea, Week 8, n=212, 2780.04 ± 1.315-0.05 ± 1.278
Urea, Week 12, n=270, 276-0.01 ± 1.2870.04 ± 1.340
Urea, Week 16, n=255, 2690.02 ± 1.3940.01 ± 1.171
Urea, Week 20, n=260, 272-0.07 ± 1.3590.04 ± 1.190
Urea, Week 24, n=261, 2680.09 ± 1.459-0.08 ± 1.154
Urea, Week 28, n=253, 2680.02 ± 1.4120.02 ± 1.230
Urea, Week 32, n=255, 2680.16 ± 1.364-0.03 ± 1.330
Urea, Week 36, n=254, 2610.05 ± 1.4510.04 ± 1.265
Urea, Week 40, n=250, 2660.07 ± 1.4660.05 ± 1.312
Urea, Week 44, n=258, 2630.12 ± 1.3610.03 ± 1.290
Urea, Week 48, n=247, 2620.09 ± 1.3620.06 ± 2.189
SecondaryChange From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase

Blood samples were collected for the analysis of clinical chemistry parameter-lipase. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · Units per liter
Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase
Units per literCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Week 4, n=278, 2761.6 ± 23.511.8 ± 30.92
Week 8, n=211, 2780.8 ± 19.070.4 ± 27.41
Week 12, n=270, 2761.3 ± 18.552.5 ± 29.44
Week 16, n=254, 2690.8 ± 20.271.2 ± 27.24
Week 20, n=260, 2701.6 ± 16.260.8 ± 27.96
Week 24, n=260, 2680.9 ± 18.740.9 ± 27.58
Week 28, n=253, 268-0.4 ± 16.731.8 ± 29.09
Week 32, n=254, 2682.9 ± 29.882.0 ± 34.42
Week 36, n=254, 2611.0 ± 17.45-0.1 ± 28.89
Week 40, n=250, 2662.3 ± 22.710.6 ± 27.95
Week 44, n=258, 2635.7 ± 41.871.6 ± 29.05
Week 48, n=247, 2610.7 ± 16.141.1 ± 32.35
SecondaryChange From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance

Blood samples were collected for the analysis of clinical chemistry parameter-creatinine clearance. GFR will be estimated by the central laboratory using the CKD-EPI. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · mL/min/1.73/m^2
Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance
mL/min/1.73/m^2CAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Week 4, n=278, 2776.9 ± 10.16-1.2 ± 8.72
Week 8, n=211, 27810.0 ± 11.830.2 ± 9.13
Week 12, n=270, 27610.7 ± 11.490.9 ± 9.83
Week 16, n=254, 26910.4 ± 11.28-0.3 ± 10.23
Week 20, n=261, 27110.9 ± 11.450.3 ± 9.90
Week 24, n=261, 26810.5 ± 11.380.2 ± 9.63
Week 28, n=253, 26810.9 ± 11.901.0 ± 9.90
Week 32, n=254, 26810.6 ± 11.451.1 ± 10.05
Week 36, n=254, 26210.3 ± 11.940.2 ± 10.08
Week 40, n=250, 26610.2 ± 12.570.7 ± 9.19
Week 44, n=258, 2639.8 ± 11.611.4 ± 9.88
Week 48, n=247, 2619.5 ± 11.35-0.7 ± 10.86
SecondaryChange From Baseline Values for Fasting Lipid Panel and Glucose Overtime Including Week 48

Blood samples were collected at Baseline and at Week 48 to assess glucose and fasting lipids which included total cholesterol, high density lipoprotein (HDL)cholesterol, low density lipoprotein (LDL) cholesterol and triglycerides. Only fasting data is presented for glucose and lipids. Baseline value is defined as the last available fasting recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at Week 48 visit (if collected while fasting) minus the Baseline value.

Time frame:
Baseline (Day 1) and at Week 48
Reported as:
Mean · Millimoles per liter
Change From Baseline Values for Fasting Lipid Panel and Glucose Overtime Including Week 48
Millimoles per literCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Glucose, Week 48, n=248, 2510.02 ± 1.2200.04 ± 0.923
Total Cholesterol, Week 48, n=240, 2390.09 ± 0.6580.05 ± 0.607
HDL cholesterol, Week 48, n=240, 2390.109 ± 0.25870.076 ± 0.2478
LDL cholesterol, Week 48, n=238, 2370.122 ± 0.5807-0.045 ± 0.5384
Triglycerides, Week 48, n=240, 239-0.085 ± 0.71670.073 ± 0.8361
SecondaryChange From Baseline Values in Urine Albumin/Creatinine Ratio and Urine Protein/Creatinine Ratio Over Time Including Week 48

Urine biomarker samples were collected for the analysis of urine albumin/creatinine ratio and urine protein/creatinine ratio. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

Time frame:
Baseline (Day 1) and at Weeks 4, 24 and 48
Reported as:
Mean · Grams per mole
Change From Baseline Values in Urine Albumin/Creatinine Ratio and Urine Protein/Creatinine Ratio Over Time Including Week 48
Grams per moleCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Urine albumin/creatinine ratio, Week 4,n=199, 1940.36 ± 6.7140.23 ± 4.062
Urine albumin/creatinine ratio, Week 24,n=137, 1840.30 ± 4.9411.06 ± 7.186
Urine albumin/creatinine ratio, Week 48,n=181, 184-0.53 ± 17.4690.19 ± 3.944
Urine protein/creatinine, Week 4, n=211, 215-0.16 ± 18.6410.19 ± 6.439
Urine protein/creatinine, Week 24, n=151, 2042.23 ± 35.1871.32 ± 12.171
Urine protein/creatinine, Week 48, n=194, 197-1.86 ± 21.8980.26 ± 8.180
SecondaryChange From Baseline Values in Urine Creatinine Over Time Including Week 48

Urine biomarker samples were collected for the analysis of urine creatinine. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

Time frame:
Baseline (Day 1) and at Weeks 4, 24 and 48
Reported as:
Mean · Micromoles per liter
Change From Baseline Values in Urine Creatinine Over Time Including Week 48
Micromoles per literCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Week 4, n=277, 272-519.5 ± 9558.55-429.0 ± 9540.31
Week 24, n=193, 258-597.4 ± 9405.95-17.1 ± 9575.04
Week 48, n=260, 258-1359.2 ± 9059.43-505.4 ± 8873.05
SecondaryChange From Baseline Values in Urine Phosphate Over Time Including Week 48

Urine biomarker samples were collected for the analysis of urine phosphate. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

Time frame:
Baseline (Day 1) and at Weeks 4, 24 and 48
Reported as:
Mean · Micromoles per liter
Change From Baseline Values in Urine Phosphate Over Time Including Week 48
Micromoles per literCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Week 4, n=275, 2731.842 ± 18.4414-0.693 ± 18.4830
Week 24, n=192, 2600.585 ± 19.2777-0.689 ± 16.9500
Week 48, n=259, 2580.043 ± 17.37410.304 ± 16.7073
SecondaryChange From Baseline Values in Urine Retinol Binding Protein Over Time Including Week 48

Urine biomarker samples were collected for the analysis of urine retinol binding protein. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

Time frame:
Baseline (Day 1) and at Week 48
Reported as:
Mean · Nanomoles per liter
Change From Baseline Values in Urine Retinol Binding Protein Over Time Including Week 48
Nanomoles per literCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Change From Baseline Values in Urine Retinol Binding Protein Over Time Including Week 48-0.33 ± 0.938-0.24 ± 0.932
SecondaryChange From Baseline Values in Urine Specific Gravity Over Time Including Week 48

Urine biomarker samples were collected for the analysis of urine specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. The urine specific gravity was measured as the ratio of urine density compared with water density.

Time frame:
Baseline (Day 1) and at Weeks 4, 24 and 48
Reported as:
Mean · Ratio of urine density to water density
Change From Baseline Values in Urine Specific Gravity Over Time Including Week 48
Ratio of urine density to water densityCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Week 4, n=271, 266-0.0004 ± 0.00837-0.0005 ± 0.00798
Week 24, n=191, 252-0.0001 ± 0.00805-0.0002 ± 0.00825
Week 48, n=255, 252-0.0009 ± 0.00784-0.0007 ± 0.00783
SecondaryChange From Baseline Values in Urine pH Over Time Including Week 48

Urine samples were collected for analysis of urine pH. pH is calculated on a scale of 0 to 14, values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH of less than 7 is acidic and a pH of greater than 7 is basic. Normal urine has a slightly acidic pH (5.0-6.0). Baseline value is defined as the last available recorded value up to and including the date of first Maintenance Phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

Time frame:
Baseline (Day 1) and at Weeks 4, 24 and 48
Reported as:
Mean · pH
Change From Baseline Values in Urine pH Over Time Including Week 48
pHCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Week 4, n=271, 2660.12 ± 0.8330.01 ± 0.884
Week 24, n=191, 252-0.01 ± 0.889-0.07 ± 0.910
Week 48, n=255, 2520.01 ± 0.926-0.10 ± 0.988
SecondaryNumber of Participants Who Discontinued or Withdrawn Due to AEs Over Time Including Week 48

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. All Maintenance Phase adverse events (start date occurring on or after the date of first dose of randomized study treatment) leading to withdrawal have been presented.

Time frame:
Up to Week 48
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued or Withdrawn Due to AEs Over Time Including Week 48
ParticipantsCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Number of Participants Who Discontinued or Withdrawn Due to AEs Over Time Including Week 4894
SecondaryPercentage Change From Baseline in Fasting Lipids Overtime Including Week 48

Blood samples were collected at Baseline and at Week 48 to assess fasting lipids which included total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides. Baseline value is defined as the last available recorded fasting value up to and including the date of first Maintenance Phase dose of IP. Percentage change from baseline is calculated as: value at Week 48 (if collected while fasting) minus Baseline value divided by Baseline value multiplied by 100.

Time frame:
Baseline (Day 1) and at Week 48
Reported as:
Mean · Millimoles per liter
Percentage Change From Baseline in Fasting Lipids Overtime Including Week 48
Millimoles per literCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Cholesterol, Week 48, Overall, n=240, 2395.09 ± 15.6952.32 ± 14.456
HDL cholesterol, Week 48, Overall, n=240, 23915.448 ± 78.52087.361 ± 20.3088
LDL cholesterol, Week 48, Overall, n=238, 2377.048 ± 29.21390.462 ± 23.9648
Triglycerides, Week 48, Overall, n=240, 2392.633 ± 44.166314.252 ± 62.2823
SecondaryNumber of Participants With Phenotypic Resistance Through Week 48

Plasma samples were collected and analyzed from participants who met confirmed virologic withdrawal criteria. Phenotypic Resistance data for following drugs :CAB,dolutegravir(DTG),elvitegravir (EVG), raltegravir(RAL),delavirdine(DLV),efavirenz(EFV),etravirine(ETR),nevirapine(NVP),RPV,lamivudine(3TC),abacavir(ABC),emtricitabine(FTC),tenofovir(TDF),zidovudine(ZDV),stavudine(d4T),didanosine(ddI),atazanavir(ATV),darunavir(DRV),fosamprenavir(FPV),indinavir(IDV),lopinavir(LPV),nelfinavir(NFV),ritonavir(RTV), saquinavir(SQV) and tipranavir (TPV) in participants meeting CVF criteria is presented.Phenotypic resistance, partially sensitive, and Sensitive were defined based on fold change(FC) value from Monogram as:resistance (FC\>clinical higher cutoff/biologic cutoff),partially sensitive (FC=clinical higher cutoff and \> clinical lower cutoff),sensitive(FC\<=clinical lower cutoff/biologic cutoff). The CVF population comprised of all participants in ITT-E population who met CVF criteria

Time frame:
Week 48
Reported as:
Count of participants · Participants
Number of Participants With Phenotypic Resistance Through Week 48
ParticipantsCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
INI, CAB, sensitive03
INI, CAB, partially sensitive00
INI, CAB, resistant30
INI, DTG, sensitive33
INI, DTG, partially sensitive00
INI, DTG, resistant00
INI, EVG, sensitive03
INI, EVG, partially sensitive00
INI, EVG, resistant30
INI, RAL, sensitive03
INI, RAL, partially sensitive00
INI, RAL, resistant30
NNRTI, DLV, sensitive13
NNRTI, DLV, partially sensitive00
NNRTI, DLV, resistant20
NNRTI, EFV, sensitive13
NNRTI, EFV, partially sensitive00
NNRTI, EFV, resistant20
NNRTI, ETR, sensitive23
NNRTI, ETR, partially sensitive10
NNRTI, ETR, resistant00
NNRTI, NVP, sensitive13
NNRTI, NVP, partially sensitive00
NNRTI, NVP, resistant20
NNRTI, RPV, sensitive13
NNRTI, RPV, partially sensitive00
NNRTI, RPV, resistant20
NRTI, 3TC, sensitive33
NRTI, 3TC, partially sensitive00
NRTI, 3TC, resistant00
NRTI, ABC, sensitive33
NRTI, ABC, partially sensitive00
NRTI, ABC, resistant00
NRTI, FTC, sensitive33
NRTI, FTC, partially sensitive00
NRTI, FTC, resistant00
NRTI, TDF, sensitive13
NRTI, TDF, partially sensitive20
NRTI, TDF, resistant00
NRTI, ZDV, sensitive23
NRTI, ZDV, partially sensitive00
NRTI, ZDV, resistant10
NRTI, d4T, sensitive33
NRTI, d4T, partially sensitive00
NRTI, d4T, resistant00
NRTI, ddI, sensitive33
NRTI, ddI, partially sensitive00
NRTI, ddI, resistant00
PI, ATV, sensitive33
PI, ATV, partially sensitive00
PI, ATV, resistant00
PI, DRV, sensitive33
PI, DRV, partially sensitive00
PI, DRV, resistant00
PI, FPV, sensitive33
PI, FPV, partially sensitive00
PI, FPV, resistant00
PI, IDV, sensitive33
PI, IDV, partially sensitive00
PI, IDV, resistant00
PI, LPV, sensitive33
PI, LPV, partially sensitive00
PI, LPV, resistant00
PI, NFV, sensitive33
PI, NFV, partially sensitive00
PI, NFV, resistant00
PI, RTV, sensitive33
PI, RTV, partially sensitive00
PI, RTV, resistant00
PI, SQV, sensitive33
PI, SQV, partially sensitive00
PI, SQV, resistant00
PI, TPV, sensitive33
PI, TPV, partially sensitive00
PI, TPV, resistant00
SecondaryNumber of Participants With Genotypic Resistance Through Week 48

Plasma samples were collected and analyzed from participants who met confirmed virologic withdrawal criteria. Genotypic Resistance data for the following drugs: DTG, EVG, RAL, DLV, EFV, ETR, NVP, RPV, 3TC, ABC, FTC, TDF, ZDV, d4T, ddI, ATV, DRV, FPV, IDV, LPV, NFV, RTV, SQV and TPV in participants meeting CVF criteria has been presented.

Time frame:
Week 48
Reported as:
Count of participants · Participants
Number of Participants With Genotypic Resistance Through Week 48
ParticipantsCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
INI, DTG, resistant00
INI, DTG, resistance possible20
INI, DTG, sensitive13
INI, EVG, resistant20
INI, EVG, resistance possible00
INI, EVG, sensitive13
INI, RAL, resistant20
INI, RAL, resistance possible00
INI, RAL, sensitive13
NNRTI, DLV, resistant00
NNRTI, DLV, resistance possible00
NNRTI, DLV, sensitive33
NNRTI, EFV, resistant00
INI, EFV, resistance possible10
NNRTI, EFV, sensitive23
NNRTI, ETR, resistant00
NNRTI, ETR, resistance possible00
NNRTI, ETR, sensitive33
NNRTI, NVP, resistant00
NNRTI, NVP, resistance possible10
NNRTI, NVP, sensitive23
NNRTI, RPV, resistant30
NNRTI, RPV, resistance possible00
NNRTI, RPV, sensitive03
NRTI, 3TC, resistant00
NNRTI, 3TC, resistance possible00
NRTI, 3TC, sensitive33
NRTI, ABC, resistant00
NRTI, ABC, resistance possible00
NRTI, ABC, sensitive33
NRTI, FTC, resistant00
NRTI, FTC, resistance possible00
NRTI, FTC, sensitive33
NRTI, TDF, resistant00
NRTI, TDF, resistance possible00
NRTI, TDF, sensitive33
NRTI, ZDV, resistant00
NRTI, ZDV, resistance possible00
NRTI, ZDV, sensitive33
NRTI, d4T, resistant00
NRTI, d4T, resistance possible00
NRTI, d4T, sensitive33
NRTI, ddI, resistant00
NRTI, ddI, resistance possible00
NRTI, ddI, sensitive33
PI, ATV, resistant00
PI, ATV, resistance possible00
PI, ATV, sensitive33
PI, ATV/r, resistant00
PI, ATV/r, resistance possible00
PI, ATV/r, sensitive33
PI, DRV/r, resistant00
PI, DRV/r, resistance possible00
PI, DRV/r, sensitive33
PI, FPV/r, resistant00
PI, FPV/r, resistance possible00
PI, FPV/r, sensitive33
PI, IDV/r, resistant00
PI, IDV/r, resistance possible00
PI, IDV/r, sensitive33
PI, LPV/r, resistant00
PI, LPV/r, resistance possible00
PI, LPV/r, sensitive33
PI, NFV, resistant00
PI, NFV, resistance possible00
PI, NFV, sensitive33
PI, RTV, resistant00
PI, RTV, resistance possible00
PI, RTV, sensitive33
PI, SQV/r, resistant00
PI, SQV/r, resistance possible00
PI, SQV/r, sensitive33
PI, TPV/r, resistant00
PI, TPV/r, resistance possible10
PI, TPV/r, sensitive23
SecondaryArea Under the Curve (AUC) for CAB LA

AUC values are Bayesian pharmacokinetic (PK) parameter estimates obtained from a population PK meta-analysis of the data collected from studies 201584 and 201585# NCT02951052. Blood samples from the current study 201584 were collected at indicated time points to analyse concentration in plasma for CAB LA. The PK Population includes all participants who received CAB and / or RPV and undergo PK sampling during the study, and provide CAB and /or RPV plasma concentration data.

Time frame:
Pre-dose at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48; 1 Week post-dose at Weeks 5, 41, 2 hours post-dose at Weeks 4 and 48
Reported as:
Geometric mean · Hours*micrograms per milliliter
Area Under the Curve (AUC) for CAB LA
Hours*micrograms per milliliterCAB LA
Area Under the Curve (AUC) for CAB LA2517.40 (2439.876 to 2597.394)
SecondaryAUC for RPV LA

AUC values are Bayesian PK parameter estimates obtained from a population PK meta-analysis of the data collected from studies 201584 and 201585# NCT02951052. Blood samples from the current study 201584 were collected at indicated time points to analyse concentration in plasma for RPV LA

Time frame:
Pre-dose at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48; 1 Week post-dose at Weeks 5, 41, 2 hours post-dose at Weeks 4 and 48
Reported as:
Geometric mean · Hours*nanograms per milliliter
AUC for RPV LA
Hours*nanograms per milliliterCAB LA
AUC for RPV LA63989.13 (61489.692 to 66590.156)
SecondaryPlasma Trough Concentration (Ctrough) for CAB LA Evaluable

Blood samples were collected at indicated time points for PK analysis of CAB LA.

Time frame:
Pre-dose at Weeks 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Geometric mean · Microgram per milliliter
Plasma Trough Concentration (Ctrough) for CAB LA Evaluable
Microgram per milliliterCAB LA
Pre-dose, Week 8, n=2501.5616 (1.4508 to 1.6808)
Pre-dose, Week 12, n=2372.0141 (1.8990 to 2.1362)
Pre-dose, Week 16, n=2152.0960 (1.9740 to 2.2255)
Pre-dose, Week 20, n=2332.1739 (2.0580 to 2.2963)
Pre-dose, Week 24, n=2272.3827 (2.2731 to 2.4976)
Pre-dose, Week 28, n=2202.4683 (2.3421 to 2.6013)
Pre-dose, Week 32, n=2192.6729 (2.5339 to 2.8196)
Pre-dose, Week 36, n=2152.8590 (2.7096 to 3.0165)
Pre-dose, Week 40, n=2102.9378 (2.7872 to 3.0966)
Pre-dose, Week 44, n=2173.0133 (2.8739 to 3.1595)
Pre-dose, Week 48, n=1973.1325 (2.9454 to 3.3315)
SecondaryCtrough for RPV LA Evaluable

Blood samples were collected at indicated time points for PK analysis of RPV LA.

Time frame:
Pre-dose at Weeks 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Geometric mean · Nanograms per milliliter
Ctrough for RPV LA Evaluable
Nanograms per milliliterRPV LA
Pre-dose, Week 8, n=25141.23 (38.74 to 43.88)
Pre-dose, Week 12, n=23646.86 (43.82 to 50.12)
Pre-dose, Week 16, n=21750.01 (47.06 to 53.15)
Pre-dose, Week 20, n=23352.76 (49.79 to 55.91)
Pre-dose, Week 24, n=22855.56 (52.48 to 58.82)
Pre-dose, Week 28, n=22059.46 (55.43 to 63.79)
Pre-dose, Week 32, n=22066.88 (62.95 to 71.05)
Pre-dose, Week 36, n=21569.09 (64.90 to 73.55)
Pre-dose, Week 40, n=21075.71 (71.38 to 80.29)
Pre-dose, Week 44, n=21677.96 (73.87 to 82.28)
Pre-dose, Week 48, n=19782.38 (77.82 to 87.22)
SecondaryMaximum Concentration (Cmax) in Plasma for CAB LA Evaluable at Week 41

Blood samples will be collected at indicated time points for PK analysis of CAB LA.

Time frame:
Week 41- 1 Week post dose
Reported as:
Geometric mean · Micrograms per milliliter
Maximum Concentration (Cmax) in Plasma for CAB LA Evaluable at Week 41
Micrograms per milliliterCAB LA
Maximum Concentration (Cmax) in Plasma for CAB LA Evaluable at Week 414.0334 (3.8488 to 4.2269)
SecondaryCmax in Plasma for RPV LA Evaluable at Week 41

Blood samples will be collected at indicated time points for PK analysis of RPV LA.

Time frame:
Week 41- 1 Week post dose
Reported as:
Geometric mean · Nanograms per milliliter
Cmax in Plasma for RPV LA Evaluable at Week 41
Nanograms per milliliterRPV LA
Cmax in Plasma for RPV LA Evaluable at Week 41106.3 (101.03 to 111.28)
Other pre-specifiedNumber of Participants With Different Demographic Parameters for Inter-subject Variability

Blood samples were planned to be collected at indicated time points for PK analysis of CAB LA and RPV LA. Demographic parameters including, but not limited to, age, sex, race, body weight, body mass index, and relevant laboratory parameters were planned to be evaluated as potential predictors of inter subject variability for pharmacokinetic parameters.

Time frame:
Up to Week 48

No measurements were reported for this outcome.

SecondaryChange From Week 5 in Dimension Scores Using Perception of Injection Questionnaire (PIN)-Last Observation Carried Forward (LOCF)

PIN questionnaire explores bother of pain at injection site and injection site reactions (ISR),anxiety before and after injection, willingness to receive HIV injectable treatment and satisfaction with mode of treatment administration of individuals receiving injection and perceptions associated with receiving injections.This measure contains 21 items: pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside clinical trial. Scores range from 1 to 5; questions are phrased to ensure that 1:most favorable perception of vaccination, and 5:most unfavorable.Dimension scores include bother from ISR, leg movement, sleep and acceptability.Score of a domain is calculated as mean of all items with domain.Higher scores represent worse perception of injection.LOCF was primary method of analysis

Time frame:
Weeks 5 and at Weeks 41 and 48
Reported as:
Mean · Scores on a scale
Change From Week 5 in Dimension Scores Using Perception of Injection Questionnaire (PIN)-Last Observation Carried Forward (LOCF)
Scores on a scaleCAB LA + RPV LA (Q4W)
Bother of ISRs, Week 41-0.14 ± 0.551
Bother of ISRs, Week 48-0.14 ± 0.639
Leg movement, Week 41-0.58 ± 0.880
Leg movement, Week 48-0.63 ± 0.964
Sleep, Week 41-0.57 ± 0.925
Sleep, Week 48-0.58 ± 1.033
Acceptance, Week 41-0.36 ± 0.959
Acceptance, Week 48-0.40 ± 0.943
Statistical analysis
  • CAB LA + RPV LA (Q4W) · Wilcoxon (Mann-Whitney) · p = <0.001 (Week 41/48 was compared with the 1st visit (Week 5) based on Wilcoxon signed-rank test, respectively. p-values are derived for 'Acceptance' only and not adjusted for multiple testing.)
SecondaryPercentage of Participants With Extremely or Very Acceptable Pain and Local Reaction: Acceptability Score on PIN Questionnaire

PIN questionnaire explores bother of pain at injection site and injection site reactions (ISR),anxiety before and after injection, willingness to receive HIV injectable treatment, following visit and satisfaction with mode of treatment administration of individuals receiving injection and perceptions associated with receiving injections.This measure contains 21 items: pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside clinical trial. Scores range from 1 to 5; questions are phrased to ensure that 1:most favorable perception of vaccination, and 5:most unfavorable.Dimension scores include bother from ISR, leg movement, sleep and acceptability.Score of a domain is calculated as mean of all items with domain.Higher scores represent worse perception of injection.LOCF was primary method of analysis.

Time frame:
Weeks 5, 41 and 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Extremely or Very Acceptable Pain and Local Reaction: Acceptability Score on PIN Questionnaire
Percentage of participantsCAB LA + RPV LA (Q4W)
Local reactions, Week 5, totally acceptable, n=27047
Local reactions,Week 5, very acceptable, n=27029
Local reactions, Week 5, moderate, n=27016
Local reactions, Week 5, little acceptable, n=2706
Local reactions, Week 5, not at all, n=2703
Pain, Week 5, totally acceptable, n=27033
Pain, Week 5, very acceptable, n=27028
Pain, Week 5, moderate acceptable, n=27024
Pain, Week 5, little acceptable, n=27011
Pain, Week 5, not at all acceptable, n=2705
Local reactions, week 41, totally, n=27657
Local reactions, Week 41, very acceptable, n=27629
Local reactions, Week 41, moderate, n=27611
Local reactions, Week 41, little acceptable, n=2763
Local reactions, Week 41, not at all, n=2761
Pain, Week 41, totally acceptable, n=27645
Pain, Week 41, very acceptable, n=27635
Pain, Week 41, moderate acceptable, n=27614
Pain, Week 41, little acceptable, n=2764
Pain, Week 41, not at all acceptable, n=2761
Local reactions, week 48, totally, n=27855
Local reactions, Week 48, very acceptable, n=27831
Local reactions, Week 48, moderate, n=27811
Local reactions, Week 48, little acceptable, n=2782
Local reactions, Week 48, not at all, n=2781
Pain, Week 48, totally acceptable, n=27849
Pain, Week 48, very acceptable, n=27835
Pain, Week 48, moderate acceptable, n=27812
Pain, Week 48 little acceptable, n=2783
Pain, Week 48, not at all acceptable, n=2781
SecondaryChange From Baseline in Life Satisfaction (LISAT) Using HIV/AIDs-targeted Quality of Life (HATQoL) Questionnaire

The HATQoL questionnaire was used to assess health related QoL (HRQoL). It comprises of three dimensions: life satisfaction (LISAT), medication worries (MEDWO) and disclosure worries (DISWO). For LISAT domain, each question is scored as 1-5, where 5 corresponds to satisfaction 'all of time' and 1 as 'none of time'. Total score for the LISAT domain (sum of item scores for questions 1a to 1d) is transformed to a 0-100 scale using formula:\[100 divided by (20 minus 4)\]\*(raw total score for LISAT minus 4). Higher the LISAT score, greater satisfaction to life. Transformed dimension score for each domain was summarized and analyzed. LOCF was used as primary method of analysis. Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI. Baseline value is defined as the last available value up to and including the date of first Maintenance phase dose of IP. Change from Baseline value is calculated as value at post-dose visit minus Baseline value.

Time frame:
Baseline (Day 1) and at Weeks 24 and 48
Reported as:
Mean · Scores on a scale
Change From Baseline in Life Satisfaction (LISAT) Using HIV/AIDs-targeted Quality of Life (HATQoL) Questionnaire
Scores on a scaleCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Week 24, n=252, 2530.4 (-1.3 to 2.1)-0.8 (-2.5 to 0.9)
Week 48, n=253, 2580.9 (-0.8 to 2.6)0.0 (-1.6 to 1.7)
Statistical analysis
  • CAB LA + RPV LA (Q4W) vs ABC/ DTG/ 3TC · ANCOVA · p = 0.307 · Adjusted difference: 1.2 · 95% CI -1.1 to 3.6Treatment comparison at Week 24 is presented, adjusted for Maintenance Baseline (Day 1) Score, Induction Baseline (Week -20) HIV-1 RNA (\<100,000, \>=100,000 c/mL), gender at birth, age (\<50, \>= 50 Years) and race (white, non-white).
  • CAB LA + RPV LA (Q4W) vs ABC/ DTG/ 3TC · ANCOVA · p = 0.472 · Adjusted difference: 0.9 · 95% CI -1.5 to 3.2Treatment comparison at Week 48 is presented, adjusted for Maintenance Baseline (Day 1) Score, Induction Baseline (Week -20) HIV-1 RNA (\<100,000, \>=100,000 c/mL), gender at birth, age (\<50, \>= 50 Years) and race (white, non-white).
SecondaryChange From Baseline in HIV Medication, MEDWO Using HATQoL

The HATQoL questionnaire was used to assess HRQoL. It comprises of three dimensions: LISAT, MEDWO and DISWO. For the MEDWO domain, each question is scored as 1-5, where 5 is associated with medication worry 'none of the time' and 1 as 'all of the time'. The total score for the MEDWO domain (sum of item scores for questions 2a to 3e) is transformed to a 0-100 scale using formula: \[100 divided by (25 minus 5)\]\* (raw total score for MEDWO minus 5). Higher MEDWO scores correspond to lower medication worries. Transformed dimension score for each domain was summarized and analyzed. LOCF was used as primary method of analysis. Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI. Baseline value is defined as the last available value up to and including the date of first Maintenance phase dose of IP. Change from Baseline value is calculated as value at post-dose visit minus Baseline value.

Time frame:
Baseline and at Weeks 24 and 48
Reported as:
Mean · Scores on a scale
Change From Baseline in HIV Medication, MEDWO Using HATQoL
Scores on a scaleCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Week 24, n=252, 2533.2 (1.6 to 4.7)1.4 (-0.1 to 3.0)
Week 48, n=253, 2581.4 (-0.3 to 3.1)1.3 (-0.4 to 3.0)
Statistical analysis
  • CAB LA + RPV LA (Q4W) vs ABC/ DTG/ 3TC · ANCOVA · p = 0.116 · Adjusted difference: 1.8 · 95% CI -0.4 to 3.9Treatment comparison at Week 24 is presented, adjusted for Maintenance Baseline (Day 1) Score, Induction Baseline (Week -20) HIV-1 RNA (\<100,000, \>=100,000 c/mL), gender at birth, age (\<50, \>= 50 Years) and race (white, non-white).
  • CAB LA + RPV LA (Q4W) vs ABC/ DTG/ 3TC · ANCOVA · p = 0.944 · Adjusted difference: 0.1 · 95% CI -2.3 to 2.5Treatment comparison at Week 48 is presented, adjusted for Maintenance Baseline (Day 1) Score, Induction Baseline (Week -20) HIV-1 RNA (\<100,000, \>=100,000 c/mL), gender at birth, age (\<50, \>= 50 Years) and race (white, non-white).
SecondaryChange From Baseline in DISWO Using HATQoL

The HATQoL questionnaire was used to assess HRQoL. It comprises of three dimensions: LISAT, MEDWO and DISWO. For the DISWO domain, each question is scored as 1-5, where 5 is associated with disclosure worry 'none of the time' and 1 as 'all of the time'. The total score for the DISWO domain (sum of item scores for questions 3a to 3e) is transformed to a 0-100 scale using formula: \[100 divided by (25 minus 5)\]\* (raw total score for DISWO minus 5). Higher DISWO total scores correspond to lower disclosure worries. Transformed dimension score for each domain was summarized and analyzed. LOCF was used as primary method of analysis. Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI. Baseline value is defined as the last available value up to and including the date of first Maintenance phase dose of IP. Change from Baseline value is calculated as value at post-dose visit minus Baseline value.

Time frame:
Baseline and at Weeks 24 and 48
Reported as:
Mean · Scores on a scale
Change From Baseline in DISWO Using HATQoL
Scores on a scaleCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Week 24, n=252, 253-0.8 (-3.9 to 2.3)0.5 (-2.6 to 3.6)
Week 48, n=253, 258-3.6 (-6.6 to -0.6)1.1 (-1.9 to 4.0)
Statistical analysis
  • CAB LA + RPV LA (Q4W) vs ABC/ DTG/ 3TC · ANCOVA · p = 0.552 · Adjusted difference: -1.3 · 95% CI -5.7 to 3.0Treatment comparison at Week 24 is presented, adjusted for Maintenance Baseline (Day 1) Score, Induction Baseline (Week -20) HIV-1 RNA (\<100,000, \>=100,000 c/mL), gender at birth, age (\<50, \>= 50 Years) and race (white, non-white).
  • CAB LA + RPV LA (Q4W) vs ABC/ DTG/ 3TC · ANCOVA · p = 0.033 · Adjusted difference: -4.6 · 95% CI -8.9 to -0.4Treatment comparison at Week 48 is presented, adjusted for Maintenance Baseline (Day 1) Score, Induction Baseline (Week -20) HIV-1 RNA (\<100,000, \>=100,000 c/mL), gender at birth, age (\<50, \>= 50 Years) and race (white, non-white).
SecondaryChange From Baseline in Health Status Using 12-item Short Form Survey (SF-12)

The SF-12 questionnaire consists of 7 questions which measures degree of general health status and mental health distress. Each question is scored 0-5, except for question 2 scored 0-3. HRQoL using SF-12 for physical component summary (PCS) and mental component summary (MCS) were assessed for two treatment groups.Missing component scores was imputed using LOCF.PCS/MCS are calculated using computer software purchased from QualityMetric (http://www.qualitymetric.com).The higher the score, the better will be the health status.Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI. Baseline value is defined as the last available recorded value up to and including the date of first Maintenance phase dose of IP. Change from Baseline value is calculated as value at post-dose visit minus Baseline value.

Time frame:
Baseline and at Weeks 24 and 48
Reported as:
Mean · Scores on a scale
Change From Baseline in Health Status Using 12-item Short Form Survey (SF-12)
Scores on a scaleCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
MCS, Week 24, n=251, 253-0.045 (-0.963 to 0.874)-1.066 (-1.980 to -0.151)
MCS, Week 48, n=252, 258-0.013 (-0.973 to 0.947)-1.116 (-2.065 to -0.167)
PCS, Week 24, n=251, 253-0.019 (-0.568 to 0.531)-0.201 (-0.748 to 0.347)
PCS, Week 48, n=252, 258-0.294 (-0.881 to 0.293)-0.126 (-0.706 to 0.455)
Statistical analysis
  • CAB LA + RPV LA (Q4W) vs ABC/ DTG/ 3TC · ANCOVA · p = 0.122 · Adjusted difference: 1.021 · 95% CI -0.275 to 2.318Treatment comparison of SF-12 MCS at Week 24 is presented, adjusted for Maintenance Baseline (Day 1) Score, Induction Baseline (Week -20) HIV-1 RNA (\<100,000, \>=100,000 c/mL), gender at birth, age (\<50, \>= 50 Years) and race (white, non-white).
  • CAB LA + RPV LA (Q4W) vs ABC/ DTG/ 3TC · ANCOVA · p = 0.109 · Adjusted difference: 1.103 · 95% CI -0.248 to 2.453Treatment comparison of SF-12 MCS at Week 48 is presented, adjusted for Maintenance Baseline (Day 1) Score, Induction Baseline (Week -20) HIV-1 RNA (\<100,000, \>=100,000 c/mL), gender at birth, age (\<50, \>= 50 Years) and race (white, non-white).
  • CAB LA + RPV LA (Q4W) vs ABC/ DTG/ 3TC · ANCOVA · p = 0.645 · Adjusted difference: 0.182 · 95% CI -0.594 to 0.958Treatment comparison of SF-12 PCS at Week 24 is presented, adjusted for Maintenance Baseline (Day 1) Score, Induction Baseline (Week -20) HIV-1 RNA (\<100,000, \>=100,000 c/mL), gender at birth, age (\<50, \>= 50 Years) and race (white, non-white).
  • CAB LA + RPV LA (Q4W) vs ABC/ DTG/ 3TC · ANCOVA · p = 0.689 · Adjusted difference: -0.169 · 95% CI -0.994 to 0.657Treatment comparison of SF-12 PCS at Week 48 is presented, adjusted for Maintenance Baseline (Day 1) Score, Induction Baseline (Week -20) HIV-1 RNA (\<100,000, \>=100,000 c/mL), gender at birth, age (\<50, \>= 50 Years) and race (white, non-white).
SecondaryChange From Baseline in Total Treatment Satisfaction Using HIV Treatment Satisfaction Questionnaire (HIVTSQs) at Weeks 4b, 24 and 44

HIVTSQs (status version) total treatment satisfaction score is computed with 1-11 items. Items 1-11 are summed to produce score with possible range of 0 to 66. Higher the score, greater improvement in satisfaction with treatment; lower score, greater the deterioration in satisfaction with treatment. A score of 0 represents no change. LOCF was primary method of analysis. Baseline value is defined as the last available value up to and including the date of first Maintenance phase dose of IP. Change from Baseline value is calculated as value at post-dose visit minus Baseline value. Adjusted mean and 95% CI of adjusted mean values has been presented.

Time frame:
Baseline and at Weeks 4b, 24 and 44
Reported as:
Mean · Scores on a scale
Change From Baseline in Total Treatment Satisfaction Using HIV Treatment Satisfaction Questionnaire (HIVTSQs) at Weeks 4b, 24 and 44
Scores on a scaleCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Week 4b, n=257, 00.2 (-0.5 to 1.0)—
Week 24, n=257, 2531.6 (0.8 to 2.5)-0.5 (-1.4 to 0.3)
Week 44, n=257, 2561.3 (0.5 to 2.1)0.5 (-0.3 to 1.4)
Statistical analysis
  • CAB LA + RPV LA (Q4W) vs ABC/ DTG/ 3TC · ANCOVA · p = <0.001 · Adjusted difference: 2.2 · 95% CI 1.0 to 3.4Treatment comparison at Week 24 is presented, adjusted for Maintenance Baseline (Day 1) Score, Induction Baseline (Week -20) HIV-1 RNA (\<100,000, \>=100,000 c/mL), gender at birth, age (\<50, \>= 50 Years) and race (white, non-white).
  • CAB LA + RPV LA (Q4W) vs ABC/ DTG/ 3TC · ANCOVA · p = 0.217 · Adjusted difference: 0.7 · 95% CI -0.4 to 1.9Treatment comparison at Week 44 is presented, adjusted for Maintenance Baseline (Day 1) Score, Induction Baseline (Week -20) HIV-1 RNA (\<100,000, \>=100,000 c/mL), gender at birth, age (\<50, \>= 50 Years) and race (white, non-white).
SecondaryChange in Treatment Satisfaction Over Time Using HIVTSQc at Week 48

HIVTSQc (change version) total treatment satisfaction score is computed with 1-11 items. Items 1-11 are summed to produce score with possible range:-33 to 33. Higher scores represent greater improvement in treatment satisfaction compared to satisfaction with treatment received during the induction phase; lower scores representedeterioration in satisfaction with treatment. A score of 0 represents no change. LOCF was primary method of analysis. Baseline value is defined as the last available value up to and including the date of first Maintenance phase dose of IP. Change from Baseline value is calculated as value at post-dose visit minus Baseline value.

Time frame:
Week 48
Reported as:
Mean · Scores on a scale
Change in Treatment Satisfaction Over Time Using HIVTSQc at Week 48
Scores on a scaleCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Change in Treatment Satisfaction Over Time Using HIVTSQc at Week 4829.6 ± 0.4925.5 ± 0.48
Statistical analysis
  • CAB LA + RPV LA (Q4W) vs ABC/ DTG/ 3TC · ANOVA · p = <0.001 · Difference: 4.1 · 95% CI 2.8 to 5.5Treatment comparison of HIVTSQc-total treatment satisfaction score at Week 48 is presented, adjusted for Induction Baseline (Week -20) HIV-1 RNA (\<100,000, \>=100,000 c/mL), gender at birth, age (\<50, \>= 50 Years) and race (white, non-white).
SecondaryChange From Baseline in Individual Item Scores of HIVTSQs at Weeks 4b, 24 and 44

HIVTSQs (status version) is a 12 item questionnaire. The individual item scores are ratedas 6 (very satisfied, convenient, flexible, etc.) to 0 (very dissatisfied, inconvenient, inflexible, etc.). Higher scores represent greater treatment satisfaction as compared to the past few weeks. LOCF was used as primary method of analysis. Baseline value is defined as the last available value up to and including the date of first Maintenance phase dose of IP. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

Time frame:
Baseline and at Weeks 4b, 24 and 44
Reported as:
Mean · Scores on a scale
Change From Baseline in Individual Item Scores of HIVTSQs at Weeks 4b, 24 and 44
Scores on a scaleCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Item 1; Week 4b, n=257, 0-0.0 ± 0.91—
Item 1; Week 24, n=257, 2550.1 ± 0.96-0.0 ± 0.95
Item 1; Week 44, n=257, 2580.0 ± 1.020.0 ± 0.93
Item 2; Week 4b, n=257, 00.0 ± 0.61—
Item 2; Week 24, n=257, 255-0.0 ± 0.62-0.0 ± 0.87
Item 2; Week 44, n=257, 258-0.1 ± 0.610.1 ± 0.62
Item 3; Week 4b, n=257, 00.2 ± 1.02—
Item 3; Week 24, n=257, 255-0.1 ± 1.21-0.0 ± 1.16
Item 3; Week 44, n=257, 258-0.0 ± 1.350.1 ± 1.22
Item 4; Week 4b, n=257, 00.1 ± 1.02—
Item 4; Week 24, n=257, 2550.1 ± 1.03-0.0 ± 1.14
Item 4; Week 44, n=257, 2580.0 ± 1.080.1 ± 1.10
Item 5; Week 4b, n=257, 00.1 ± 0.98—
Item 5; Week 24, n=257, 2550.4 ± 1.22-0.1 ± 1.05
Item 5; Week 44, n=257, 2580.3 ± 1.280.0 ± 1.06
Item 6; Week 4b, n=257, 00.1 ± 1.40—
Item 6; Week 24, n=257, 2550.3 ± 1.47-0.1 ± 1.63
Item 6; Week 44, n=257, 2580.3 ± 1.700.2 ± 1.48
Item 7; Week 4b, n=257, 00.0 ± 0.83—
Item 7; Week 24, n=257, 2550.0 ± 0.790.0 ± 1.02
Item 7; Week 44, n=257, 2580.1 ± 0.850.1 ± 0.95
Item 8; Week 4b, n=257, 0-0.0 ± 1.06—
Item 8; Week 24, n=257, 2550.2 ± 1.22-0.0 ± 1.11
Item 8; Week 44, n=257, 2580.2 ± 1.270.1 ± 1.16
Item 9; Week 4b, n=257, 0-0.1 ± 0.85—
Item 9; Week 24, n=257, 2550.0 ± 0.78-0.1 ± 1.11
Item 9; Week 44, n=257, 2580.0 ± 0.850.0 ± 1.01
Item 10; Week 4b, n=257, 0-0.1 ± 1.16—
Item 10; Week 24, n=257, 2560.4 ± 1.28-0.1 ± 1.35
Item 10; Week 44, n=257, 2590.4 ± 1.33-0.0 ± 1.20
Item 11; Week 4b, n=257, 0-0.0 ± 1.02—
Item 11; Week 24, n=257, 2550.2 ± 1.18-0.1 ± 0.99
Item 11; Week 44, n=257, 2580.1 ± 1.180.0 ± 0.97
Item 12; Week 4b, n=257, 0-0.0 ± 0.99—
Item 12; Week 24, n=257, 255-0.4 ± 1.260.1 ± 1.19
Item 12; Week 44, n=257, 258-0.5 ± 1.200.1 ± 1.29
SecondaryChange From Baseline in Treatment Acceptance at Weeks 8, 24 and 48 Using "General Acceptance" Dimension of the Chronic Treatment Acceptance (ACCEPT) Questionnaire

ACCEPT questionnaire is generic medication acceptance measure assessing how participants weigh advantages and disadvantages of long-term medication. It consists 25 items, capturing six dimensions. 3 questions focusing on general acceptance of study medication were analyzed. Items scores are rated as 1-5 :1-totally disagree,2-somewhat disagree,3-somewhat agree,4-totally agree and 5-I don't know. The acceptance domain score (ranging from 0 to 100) is calculated using the following formula:100\*(mean of recoded items in dimension minus 1) divided by 2.LOCF was primary method of analysis. Measure type is mean for adjusted mean and dispersion measure: 95% CI. Baseline value is defined as the last available value up to and including the date of first Maintenance phase dose of IP. Change from Baseline value is calculated as value at post-dose visit minus Baseline value.

Time frame:
Baseline and at Weeks 8, 24 and 48
Reported as:
Mean · Scores on a scale
Change From Baseline in Treatment Acceptance at Weeks 8, 24 and 48 Using "General Acceptance" Dimension of the Chronic Treatment Acceptance (ACCEPT) Questionnaire
Scores on a scaleCAB LA + RPV LA (Q4W)ABC/ DTG/ 3TC
Week 8, n=253, 2563.3 (0.8 to 5.8)1.2 (-1.3 to 3.6)
Week 24, 255, 2613.7 (1.1 to 6.4)1.1 (-1.5 to 3.7)
Week 48, n=255, 2623.0 (0.4 to 5.6)0.8 (-1.7 to 3.4)
Statistical analysis
  • CAB LA + RPV LA (Q4W) vs ABC/ DTG/ 3TC · ANCOVA · p = 0.232 · Adjusted difference: 2.2 · 95% CI -1.4 to 5.7Treatment comparison at Week 8 is presented, adjusted for Maintenance Baseline (Day 1) Score, Induction Baseline (Week -20) HIV-1 RNA (\<100,000, \>=100,000 c/mL), gender at birth, age (\<50, \>= 50 Years) and race (white, non-white).
  • CAB LA + RPV LA (Q4W) vs ABC/ DTG/ 3TC · ANCOVA · p = 0.154 · Adjusted difference: 2.7 · 95% CI -1.0 to 6.4Treatment comparison Week 24 is presented, adjusted for Maintenance Baseline (Day 1) Score, Induction Baseline (Week -20) HIV-1 RNA (\<100,000, \>=100,000 c/mL), gender at birth, age (\<50, \>= 50 Years) and race (white, non-white).
  • CAB LA + RPV LA (Q4W) vs ABC/ DTG/ 3TC · ANCOVA · p = 0.236 · Adjusted difference: 2.2 · 95% CI -1.4 to 5.8Treatment comparison at Week 48 is presented, adjusted for Maintenance Baseline (Day 1) Score, Induction Baseline (Week -20) HIV-1 RNA (\<100,000, \>=100,000 c/mL), gender at birth, age (\<50, \>= 50 Years) and race (white, non-white).
SecondaryChange From 4b in Tolerability of Injection at Weeks 5, 40 and 41 Using Numeric Rating Scale (NRS) Within CAB LA+RPV LA Arm

The NRS questionnaire is used to assess the tolerability of injections in CAB LA+RPV LA arm only. The questionnaire consists of one single question and will assess maximum level of pain experienced with the most recent injections ranking from no pain (0) to extreme pain (10). Missing scores was imputed using LOCF.

Time frame:
Weeks 4b, 5, 40 and 41
Reported as:
Mean · Scores on a scale
Change From 4b in Tolerability of Injection at Weeks 5, 40 and 41 Using Numeric Rating Scale (NRS) Within CAB LA+RPV LA Arm
Scores on a scaleCAB LA + RPV LA (Q4W)
Week 51.8 ± 2.78
Week 400.8 ± 2.72
Week 410.4 ± 2.69

Adverse events

Collected over Non-serious AEs and SAEs were collected up to an average of 59 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CAB LA+RPV LA (Q4W)0/283 (0%)18/283 (6.4%)252/283 (89%)
ABC/ DTG/ 3TC0/283 (0%)12/283 (4.2%)138/283 (48.8%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventCAB LA+RPV LA (Q4W)ABC/ DTG/ 3TC
Hepatitis AInfections and infestations3/2831/283
Anogenital wartsNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2831/283
Adenocarcinoma of colonNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2830/283
Anal abscessInfections and infestations0/2831/283
Anal fistulaGastrointestinal disorders1/2830/283
ArthritisMusculoskeletal and connective tissue disorders1/2830/283
Bile duct stoneHepatobiliary disorders1/2830/283
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2831/283
Bronchitis pneumococcalInfections and infestations0/2831/283
CholecystitisHepatobiliary disorders1/2830/283
Most frequent other events
Showing 10 of 18
Most frequent other events
EventCAB LA+RPV LA (Q4W)ABC/ DTG/ 3TC
Injection site painGeneral disorders227/2830/283
NasopharyngitisInfections and infestations56/28348/283
Injection site noduleGeneral disorders44/2830/283
HeadacheNervous system disorders39/28321/283
Upper respiratory tract infectionInfections and infestations38/28328/283
Injection site indurationGeneral disorders38/2830/283
DiarrhoeaGastrointestinal disorders32/28325/283
InfluenzaInfections and infestations25/28320/283
Vitamin D deficiencyMetabolism and nutrition disorders23/28313/283
Injection site swellingGeneral disorders23/2830/283

Baseline characteristics

Age, Continuous
Age, Continuous(Years)CAB LA + RPV LA (Q4W)ABC/ DTG/ 3TCTotal
Mean35.9 ± 10.1736.0 ± 9.8235.9 ± 9.99
Sex: Female, Male
Sex: Female, Male(Participants)CAB LA + RPV LA (Q4W)ABC/ DTG/ 3TCTotal
Female6364127
Male220219439
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)CAB LA + RPV LA (Q4W)ABC/ DTG/ 3TCTotal
American Indian or Alaska Native369
Asian-Central/South Asian Heritage213
Asian-East Asian Heritage123
Asian-South East Asian Heritage101
Asian-Japanese Heritage81220
Black or African American4756103
Native Hawaiian or other Pacific Islander101
White-Arabic/North African Heritage538
White-White /Caucasian/European Heritage211198409
Multiple437
Missing022
08

Study locations

108 sites
  • GSK Investigational Site
    Birmingham, Alabama 35294, United States
  • GSK Investigational Site
    Bakersfield, California 93301, United States
  • GSK Investigational Site
    Long Beach, California 90813, United States
  • GSK Investigational Site
    Los Angeles, California 90019, United States
  • GSK Investigational Site
    Los Angeles, California 90027, United States
  • GSK Investigational Site
    San Francisco, California 94109, United States
  • GSK Investigational Site
    Aurora, Colorado 80045, United States
  • GSK Investigational Site
    Washington D.C., District of Columbia 20005, United States
  • GSK Investigational Site
    Fort Lauderdale, Florida 33316, United States
  • GSK Investigational Site
    Orlando, Florida 32806, United States
  • GSK Investigational Site
    Atlanta, Georgia 30312, United States
  • GSK Investigational Site
    Augusta, Georgia 30912-3130, United States
  • GSK Investigational Site
    Macon, Georgia 31201, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46202, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55415, United States
  • GSK Investigational Site
    Omaha, Nebraska 68198, United States
  • GSK Investigational Site
    Camden, New Jersey 08103, United States
  • GSK Investigational Site
    New York, New York 10029, United States
  • GSK Investigational Site
    Providence, Rhode Island 02904, United States
  • GSK Investigational Site
    Austin, Texas 78705, United States
  • GSK Investigational Site
    Bellaire, Texas 77401, United States
  • GSK Investigational Site
    Dallas, Texas 75246, United States
  • GSK Investigational Site
    Fort Worth, Texas 76104, United States
  • GSK Investigational Site
    Longview, Texas 75605, United States
  • GSK Investigational Site
    Lynchburg, Virginia 24501, United States
  • GSK Investigational Site
    Vancouver, British Columbia V6Z 2C7, Canada
  • GSK Investigational Site
    Ottawa, Ontario K1H 8L6, Canada
  • GSK Investigational Site
    Toronto, Ontario M5B 1W8, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 1K2, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 2N2, Canada
  • GSK Investigational Site
    Montreal, Quebec H2L 4P9, Canada
  • GSK Investigational Site
    Bobigny, 93009, France
  • GSK Investigational Site
    Lyon, 69437, France
  • GSK Investigational Site
    Marseille, 13003, France
  • GSK Investigational Site
    Paris, 75018, France
  • GSK Investigational Site
    Paris, 75475, France
  • GSK Investigational Site
    Paris, 75571, France
  • GSK Investigational Site
    Paris, 75651, France
  • GSK Investigational Site
    Paris, 75970, France
  • GSK Investigational Site
    Berlin, 10439, Germany
  • GSK Investigational Site
    Berlin, 10787, Germany
  • GSK Investigational Site
    Bonn, 53127, Germany
  • GSK Investigational Site
    Essen, 45122, Germany
  • GSK Investigational Site
    Frankfurt, 60590, Germany
  • GSK Investigational Site
    Frankfurt, 60596, Germany
  • GSK Investigational Site
    Hamburg, 20146, Germany
  • GSK Investigational Site
    Hamburg, 20246, Germany
  • GSK Investigational Site
    Hanover, 30625, Germany
  • GSK Investigational Site
    München, 80336, Germany
  • GSK Investigational Site
    München, 80337, Germany
  • GSK Investigational Site
    Brescia, 25123, Italy
  • GSK Investigational Site
    Milan, 20127, Italy
  • GSK Investigational Site
    Milan, 20157, Italy
  • GSK Investigational Site
    Monza MB, 20900, Italy
  • GSK Investigational Site
    Roma, 00149, Italy
  • GSK Investigational Site
    Aichi, 460-0001, Japan
  • GSK Investigational Site
    Osaka, 540-0006, Japan
  • GSK Investigational Site
    Tokyo, 162-8655, Japan
  • GSK Investigational Site
    Amsterdam, 1105 AZ, Netherlands
  • GSK Investigational Site
    Groningen, 9713 GZ, Netherlands
  • GSK Investigational Site
    Rotterdam, 3079 DZ, Netherlands
  • GSK Investigational Site
    Utrecht, 3584 CX, Netherlands
  • GSK Investigational Site
    Kazan', 420061, Russia
  • GSK Investigational Site
    Kemerovo, 650056, Russia
  • GSK Investigational Site
    Krasnodar, 350015, Russia
  • GSK Investigational Site
    Lipetsk, 398043, Russia
  • GSK Investigational Site
    Moscow, 115035, Russia
  • GSK Investigational Site
    Oryol, 302040, Russia
  • GSK Investigational Site
    Saint Petersburg, 190020, Russia
  • GSK Investigational Site
    Saint Petersburg, 193167, Russia
  • GSK Investigational Site
    Saint Petersburg, 196645, Russia
  • GSK Investigational Site
    Saratov, 410009, Russia
  • GSK Investigational Site
    Smolensk, 214006, Russia
  • GSK Investigational Site
    Toliyatti, 445846, Russia
  • GSK Investigational Site
    Yekaterinburg, 620102, Russia
  • GSK Investigational Site
    Bloemfontein, 9301, South Africa
  • GSK Investigational Site
    Cape Town, 7925, South Africa
  • GSK Investigational Site
    Durban, 4052, South Africa
  • GSK Investigational Site
    Durban, 4091, South Africa
  • GSK Investigational Site
    Johannesburg, 2113, South Africa
  • GSK Investigational Site
    Middelburg, 1055, South Africa
  • GSK Investigational Site
    Pretoria, 0087, South Africa
  • GSK Investigational Site
    Winnie Mandela, 9400, South Africa
  • GSK Investigational Site
    A Coruña, 15006, Spain
  • GSK Investigational Site
    Barcelona, 08025, Spain
  • GSK Investigational Site
    Barcelona, 08907, Spain
  • GSK Investigational Site
    Bilbao, 48013, Spain
  • GSK Investigational Site
    Elche Alicante, 03203, Spain
  • GSK Investigational Site
    Ferrol, 15405, Spain
  • GSK Investigational Site
    Granada, 18016, Spain
  • GSK Investigational Site
    La Laguna Santa Cruz, 38320, Spain
  • GSK Investigational Site
    Madrid, 28040, Spain
  • GSK Investigational Site
    Madrid, 28041, Spain
  • GSK Investigational Site
    Madrid, 28046, Spain
  • GSK Investigational Site
    Murcia, 30003, Spain
  • GSK Investigational Site
    Murcia, 30120, Spain
  • GSK Investigational Site
    Palma de Mallorca, 07010, Spain
  • GSK Investigational Site
    Palma de Mallorca, 07198, Spain
  • GSK Investigational Site
    San SebastiAn de Los Rey, 28702, Spain
  • GSK Investigational Site
    Santa Cruz de Tenerife, 38010, Spain

Showing the first 100 of 108 sites across 11 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Orkin C, Arasteh K, Gorgolas Hernandez-Mora M, Pokrovsky V, Overton ET, Girard PM, Oka S, Walmsley S, Bettacchi C, Brinson C, Philibert P, Lombaard J, St Clair M, Crauwels H, Ford SL, Patel P, Chounta V, D'Amico R, Vanveggel S, Dorey D, Cutrell A, Griffith S, Margolis DA, Williams PE, Parys W, Smith KY, Spreen WR. Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection. N Engl J Med. 2020 Mar 19;382(12):1124-1135. doi: 10.1056/NEJMoa1909512. Epub 2020 Mar 4. PubMed 32130806 ↗
  • D'Amico R, Han K, Min S, DeMoor R, St Clair M, Ford SL, Harrington C, Bernal-Morell E, Lombaard J, Crauwels H, Kolobova I, Patel N, Jamil N, Van Solingen-Ristea R, Acuipil C, Spreen W. Subcutaneous injections of cabotegravir plus rilpivirine long-acting in virally suppressed adults with HIV-1. AIDS. 2025 Dec 1;39(15):2182-2190. doi: 10.1097/QAD.0000000000004310. Epub 2025 Oct 21. PubMed 40779489 ↗
  • Okesanya OJ, Ayeni RA, Amadin P, Ngwoke I, Amisu BO, Ukoaka BM, Ahmed MM, Oso TA, Musa SS, Lucero-Prisno DE. Advances in HIV Treatment and Vaccine Development: Emerging Therapies and Breakthrough Strategies for Long-Term Control. AIDS Res Treat. 2025 Jul 4;2025:6829446. doi: 10.1155/arat/6829446. eCollection 2025. PubMed 40655875 ↗
  • Elliot ER, Polli JW, Patel P, Garside L, Grove R, Barnett V, Roberts J, Byrapuneni S, Crauwels H, Ford SL, Van Solingen-Ristea R, Birmingham E, D'Amico R, Baugh B, van Wyk J. Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials. J Infect Dis. 2024 Jul 25;230(1):e34-e42. doi: 10.1093/infdis/jiad580. PubMed 39052748 ↗
  • Chounta V, Byrnes HF, Henry-Szatkowski M, Browning D, Donatti C, Lambert J. Psychometric Validation of the Perception of Injection (PIN) Questionnaire Using Data From Two Phase III, Open-Label, Active-Controlled, Non-Inferiority Studies in People Living With HIV. Adv Ther. 2023 Dec;40(12):5300-5314. doi: 10.1007/s12325-023-02656-1. Epub 2023 Sep 30. PubMed 37776478 ↗
  • Moreno S, Rivero A, Ventayol P, Falco V, Torralba M, Schroeder M, Neches V, Vallejo-Aparicio LA, Mackenzie I, Turner M, Harrison C. Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain. Infect Dis Ther. 2023 Aug;12(8):2039-2055. doi: 10.1007/s40121-023-00840-y. Epub 2023 Jul 14. PubMed 37452174 ↗
  • Masia M, Fernandez-Gonzalez M, Agullo V, Mascarell P, Padilla S, Garcia-Abellan J, Gutierrez F. Human Immunodeficiency Virus Type 1 RNA Levels in Rectal and Seminal Compartments After Switching to Long-Acting Cabotegravir Plus Rilpivirine: A Longitudinal Study. Clin Infect Dis. 2023 Feb 8;76(3):e748-e751. doi: 10.1093/cid/ciac676. PubMed 35986671 ↗
  • Chounta V, Snedecor SJ, Wu S, Van de Velde N. Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV-1-infection. BMC Infect Dis. 2022 May 4;22(1):428. doi: 10.1186/s12879-022-07243-3. PubMed 35508986 ↗
  • Jeffrey JL, St Clair M, Wang P, Wang C, Li Z, Beloor J, Talarico C, Fridell R, Krystal M, White CT, Griffith S, D'Amico R, Smith K, Van Eygen V, Vingerhoets J, Vandermeulen K, Spreen W, van Lunzen J. Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the In Vitro Potency of Cabotegravir or Rilpivirine. Antimicrob Agents Chemother. 2022 Mar 15;66(3):e0170221. doi: 10.1128/AAC.01702-21. Epub 2022 Jan 3. PubMed 34978890 ↗
  • Orkin C, Bernal Morell E, Tan DHS, Katner H, Stellbrink HJ, Belonosova E, DeMoor R, Griffith S, Thiagarajah S, Van Solingen-Ristea R, Ford SL, Crauwels H, Patel P, Cutrell A, Smith KY, Vandermeulen K, Birmingham E, St Clair M, Spreen WR, D'Amico R. Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study. Lancet HIV. 2021 Nov;8(11):e668-e678. doi: 10.1016/S2352-3018(21)00184-3. Epub 2021 Oct 14. PubMed 34656207 ↗
  • Orkin C, Oka S, Philibert P, Brinson C, Bassa A, Gusev D, Degen O, Garcia JG, Morell EB, Tan DHS, D'Amico R, Dorey D, Griffith S, Thiagarajah S, St Clair M, Van Solingen-Ristea R, Crauwels H, Ford SL, Patel P, Chounta V, Vanveggel S, Cutrell A, Van Eygen V, Vandermeulen K, Margolis DA, Smith KY, Spreen WR. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study. Lancet HIV. 2021 Apr;8(4):e185-e196. doi: 10.1016/S2352-3018(20)30340-4. PubMed 33794181 ↗
  • Rizzardini G, Overton ET, Orkin C, Swindells S, Arasteh K, Gorgolas Hernandez-Mora M, Pokrovsky V, Girard PM, Oka S, Andrade-Villanueva JF, Richmond GJ, Baumgarten A, Masia M, Latiff G, Griffith S, Harrington CM, Hudson KJ, St Clair M, Talarico CL, Patel P, Cutrell A, Van Eygen V, D'Amico R, Mrus JM, Wu S, Ford SL, Chow K, Roberts J, Wills A, Walters N, Vanveggel S, Van Solingen-Ristea R, Crauwels H, Smith KY, Spreen WR, Margolis DA. Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials. J Acquir Immune Defic Syndr. 2020 Dec 1;85(4):498-506. doi: 10.1097/QAI.0000000000002466. PubMed 33136751 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2016 to primary completion in Aug 2018, 22 months.

Results were first posted in Oct 2019, 1 year 1 month after primary completion.

Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 22 months is close to that.

Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2016
First posted
Oct 19, 2016
StartActual
Oct 27, 2016
Primary completionActual
Aug 30, 2018
CompletionEst.
Dec 31, 2029
Results first posted
Oct 29, 2019
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02938520
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
Oct 19, 2016
Start date
Oct 27, 2016
Primary completion
Aug 30, 2018
Completion
Dec 31, 2029 (estimated)
Results posted
Oct 29, 2019
Last update
Jul 30, 2026

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabotegravir

Start the discussion